

Peer Reviewed Original Publications:

1-231232-390

1. Moch H, Oberholzer M, Christen H, Buser M, Dalquen P, Wegmann W, Gudat F. Diagnostic tools for differentiating pleural mesothelioma from lung adenocarcinoma in paraffin embedded tissue. II. Design of an expert system and its application to the diagnosis of mesothelioma. *Virchows Arch A Pathol Anat Histopathol* 1993; 423(6):493-6.
2. Moch H, Oberholzer M, Dalquen P, Wegmann W, Gudat F. Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: Immunohistochemical findings. *Virchows Arch A Pathol Anat Histopathol* 1993; 423(1):19-27.
3. Moch H, Sauter G, Moore D, Mihatsch MJ, Gudat F, Waldman F. p53 and erbB-2 protein overexpression are associated with early invasion and metastasis in bladder cancer. *Virchows Arch A Pathol Anat Histopathol* 1993; 423(5):329-34.
4. Moch H, Torhorst J, Durmuller U, Feichter GE, Sauter G, Gudat F. Comparative analysis of the expression of tenascin and established prognostic factors in human breast cancer. *Pathol Res Pract* 1993; 189(5):510-4.
5. Sauter G, Moch H, Moore D, Carroll P, Kerschmann R, Chew K, Mihatsch MJ, Gudat F, Waldman F. Heterogeneity of erbB-2 gene amplification in bladder cancer. *Cancer Res* 1993; 53():2199-203.
6. Moch H, Sauter G, Mihatsch MJ, Gudat F, Epper R, Waldman FM. p53 but not erbB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer. *Hum Pathol* 1994; 25(12):1346-51.
7. Sauter G, Deng G, Moch H, Kerschmann R, Matsumura K, De Vries S, George T, Fuentes J, Carroll P, Mihatsch MJ, et al. Physical deletion of the p53 gene in bladder cancer. Detection by fluorescence in situ hybridization. *Am J Pathol* 1994; 144(4):756-66.
8. Sauter G, Haley J, Chew K, Kerschmann R, Moore D, Carroll P, Moch H, Gudat F, Mihatsch MJ, Waldman F. Epidermal-growth-factor-receptor expression is associated with rapid tumor proliferation in bladder cancer. *Int J Cancer* 1994; 57(4):508-14.
9. Sauter G, Carroll P, Moch H, Kallioniemi A, Kerschmann R, Narayan P, Mihatsch MJ, Waldman FM. c-myc copy number gains in bladder cancer detected by fluorescence in situ hybridization. *Am J Pathol* 1995; 146(5):1131-9.
10. Sauter G, Moch H, Carroll P, Kerschmann R, Mihatsch MJ, Waldman FM. Chromosome-9 loss detected by fluorescence in situ hybridization in bladder cancer. *Int J Cancer* 1995; 64(2):99-103.
11. Sauter G, Moch H, Gasser TC, Mihatsch MJ, Waldman FM. Heterogeneity of chromosome 17 and erbB-2 gene copy number in primary and metastatic bladder cancer. *Cytometry* 1995; 21(1):40-6.
12. Sauter G, Moch H, Wagner U, Novotna H, Gasser TC, Mattarelli G, Mihatsch MJ, Waldman FM. Y chromosome loss detected by FISH in bladder cancer. *Cancer Genet Cytogenet* 1995; 82(2):163-9.

13. Wagner U, Sauter G, Moch H, Novotna H, Epper R, Mihatsch MJ, Waldman FM. Patterns of p53, erbB-2, and EGF-r expression in premalignant lesions of the urinary bladder. *Hum Pathol* 1995; 26(9):970-8.
14. Bubendorf L, Sauter G, Moch H, Jordan P, Blochlinger A, Gasser TC, Mihatsch MJ. Prognostic significance of Bcl-2 in clinically localized prostate cancer. *Am J Pathol* 1996; 148(5):1557-65.
15. Bubendorf L, Sauter G, Moch H, Schmid HP, Gasser TC, Jordan P, Mihatsch MJ. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. *J Pathol* 1996; 178(4):437-41.
16. Moch H, Presti JC, Jr., Sauter G, Buchholz N, Jordan P, Mihatsch MJ, Waldman FM. Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. *Cancer Res* 1996; 56(1):27-30.
17. Presti JC, Jr., Moch H, Reuter VE, Cordon-Cardo C, Waldman FM. Renal cell carcinoma genetic analysis by comparative genomic hybridization and restriction fragment length polymorphism analysis. *J Urol* 1996; 156(1):281-5.
18. Presti JC, Jr., Moch H, Reuter VE, Huynh D, Waldman FM. Comparative genomic hybridization for genetic analysis of renal oncocytomas. *Genes Chromosomes Cancer* 1996; 17(4):199-204.
19. Sauter G, Feichter G, Torhorst J, Moch H, Novotna H, Wagner U, Durmuller U, Waldman FM. Fluorescence in situ hybridization for detecting erbB-2 amplification in breast tumor fine needle aspiration biopsies. *Acta Cytol* 1996; 40(2):164-73.
20. Dalquen P, Moch H, Feichter G, Lehmann M, Soler M, Stulz P, Jordan P, Torhorst J, Mihatsch MJ, Sauter G. DNA aneuploidy, S-phase fraction, nuclear p53 positivity, and survival in non-small-cell lung carcinoma. *Virchows Arch* 1997; 431(3):173-9.
21. Dellas A, Moch H, Schultheiss E, Feichter G, Almendral AC, Gudat F, Torhorst J. Angiogenesis in cervical neoplasia: microvessel quantitation in precancerous lesions and invasive carcinomas with clinicopathological correlations. *Gynecol Oncol* 1997; 67(1):27-33.
22. Dellas A, Schultheiss E, Almendral AC, Gudat F, Oberholzer M, Feichter G, Moch H, Torhorst J. Altered expression of mdm-2 and its association with p53 protein status, tumor-cell-proliferation rate and prognosis in cervical neoplasia. *Int J Cancer* 1997; 74(4):421-5.
23. Moch H, Sauter G, Buchholz N, Gasser TC, Bubendorf L, Waldman FM, Mihatsch MJ. Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma. *Hum Pathol* 1997; 28(11):1255-9.
24. Moch H, Sauter G, Gasser TC, Buchholz N, Bubendorf L, Richter J, Jiang F, Dellas A, Mihatsch MJ. p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma. *Urol Res* 1997; 25 Suppl 1:S25-30.
25. Richter J, Jiang F, Gorog JP, Sartorius G, Egenter C, Gasser TC, Moch H, Mihatsch MJ, Sauter G. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. *Cancer Res* 1997; 57(14):2860-4.
26. Sauter G, Gasser TC, Moch H, Richter J, Jiang F, Albrecht R, Novotny H, Wagner U, Bubendorf L, Mihatsch MJ. DNA aberrations in urinary bladder cancer detected by flow cytometry and FISH. *Urol Res* 1997; 25 Suppl 1:S37-43.

27. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJ, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Moch H, Zbar B, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. *Nat Genet* 1997; 16(1):68-73.
28. Wagner U, Bubendorf L, Gasser TC, Moch H, Gorog JP, Richter J, Mihatsch MJ, Waldman FM, Sauter G. Chromosome 8p deletions are associated with invasive tumor growth in urinary bladder cancer. *Am J Pathol* 1997; 151(3):753-9.
29. Bubendorf L, Tapia C, Gasser TC, Casella R, Grunder B, Moch H, Mihatsch MJ, Sauter G. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. *Hum Pathol* 1998; 29(9):949-54.
30. Casella R, Bubendorf L, Sauter G, Moch H, Mihatsch MJ, Gasser TC. Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies. *J Urol* 1998; 160(2):406-10.
31. Dellas A, Schultheiss E, Leivas MR, Moch H, Torhorst J. Association of p27Kip1, cyclin E and c-myc expression with progression and prognosis in HPV-positive cervical neoplasms. *Anticancer Res* 1998; 18(6A):3991-8.
32. Jiang F, Moch H, Richter J, Egenter C, Gasser T, Bubendorf L, Gschwind R, Sauter G, Mihatsch MJ. Comparative genomic hybridization reveals frequent chromosome 13q and 4q losses in renal carcinomas with sarcomatoid transformation. *J Pathol* 1998; 185(4):382-8.
33. Jiang F, Richter J, Schraml P, Bubendorf L, Gasser T, Sauter G, Mihatsch MJ, Moch H. Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes. *Am J Pathol* 1998; 153(5):1467-73.
34. Moch H, Sauter G, Gasser TC, Bubendorf L, Richter J, Presti JC, Jr., Waldman FM, Mihatsch MJ. EGF-r gene copy number changes in renal cell carcinoma detected by fluorescence in situ hybridization. *J Pathol* 1998; 184(4):424-9.
35. Moch H, Schraml P, Bubendorf L, Richter J, Gasser TC, Mihatsch MJ, Sauter G. Intratumoral heterogeneity of von Hippel-Lindau gene deletions in renal cell carcinoma detected by fluorescence in situ hybridization. *Cancer Res* 1998; 58(11):2304-9.
36. Presti JC, Jr., Moch H, Gelb AB, Huynh D, Waldman FM. Initiating genetic events in small renal neoplasms detected by comparative genomic hybridization. *J Urol* 1998; 160(4):1557-61.
37. Richter J, Beffa L, Wagner U, Schraml P, Gasser TC, Moch H, Mihatsch MJ, Sauter G. Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization. *Am J Pathol* 1998; 153(5):1615-21.
38. Bissig H, Richter J, Desper R, Meier V, Schraml P, Schaffer AA, Sauter G, Mihatsch MJ, Moch H. Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization. *Am J Pathol* 1999; 155(1):267-74.
39. Bubendorf L, Kolmer M, Kononen J, Koivisto P, Mousses S, Chen Y, Mahlamaki E, Schraml P, Moch H, Willi N, Elkahloun AG, Pretlow TG, Gasser TC, Mihatsch MJ, Sauter G, Kallioniemi OP. Hormone therapy failure in human prostate cancer: analysis

- by complementary DNA and tissue microarrays. *J Natl Cancer Inst* 1999; 91(20):1758-64.
40. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G, Kallioniemi OP. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. *Cancer Res* 1999; 59(4):803-6.
 41. Dellas A, Torhorst J, Jiang F, Proffitt J, Schultheiss E, Holzgreve W, Sauter G, Mihatsch MJ, Moch H. Prognostic value of genomic alterations in invasive cervical squamous cell carcinoma of clinical stage IB detected by comparative genomic hybridization. *Cancer Res* 1999; 59(14):3475-9.
 42. Desper R, Jiang F, Kallioniemi OP, Moch H, Papadimitriou CH, Schaffer AA. Inferring tree models for oncogenesis from comparative genome hybridization data. *J Comput Biol* 1999; 6(1):37-51.
 43. Meli ML, Carrel F, Waibel R, Amstutz H, Crompton N, Jaussi R, Moch H, Schubiger PA, Novak-Hofer I. Anti-neuroblastoma antibody chCE7 binds to an isoform of L1-CAM present in renal carcinoma cells. *Int J Cancer* 1999; 83(3):401-8.
 44. Moch H, Schraml P, Bubendorf L, Mirlacher M, Kononen J, Gasser T, Mihatsch MJ, Kallioniemi OP, Sauter G. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. *Am J Pathol* 1999; 154(4):981-6.
 45. Neuhaus M, Wagner U, Schmid U, Ackermann D, Zellweger T, Maurer R, Alund G, Knonagel H, Rist M, Moch H, Mihatsch MJ, Gasser TC, Sauter G. Polysomies but not Y chromosome losses have prognostic significance in pTa/pT1 urinary bladder cancer. *Hum Pathol* 1999; 30(1):81-6.
 46. Richter J, Wagner U, Schraml P, Maurer R, Alund G, Knonagel H, Moch H, Mihatsch MJ, Gasser TC, Sauter G. Chromosomal imbalances are associated with a high risk of progression in early invasive (pT1) urinary bladder cancer. *Cancer Res* 1999; 59(22):5687-91.
 47. Schraml P, Kononen J, Bubendorf L, Moch H, Bissig H, Nocito A, Mihatsch MJ, Kallioniemi OP, Sauter G. Tissue microarrays for gene amplification surveys in many different tumor types. *Clin Cancer Res* 1999; 5(8):1966-75.
 48. Speel EJ, Richter J, Moch H, Egenter C, Saremaslani P, Rutimann K, Zhao J, Barghorn A, Roth J, Heitz PU, Komminoth P. Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization. *Am J Pathol* 1999; 155(6):1787-94.
 49. Terracciano L, Richter J, Tornillo L, Beffa L, Diener PA, Maurer R, Gasser TC, Moch H, Mihatsch MJ, Sauter G. Chromosomal imbalances in small cell carcinomas of the urinary bladder. *J Pathol* 1999; 189(2):230-5.
 50. Wagner U, Suess K, Luginbuhl T, Schmid U, Ackermann D, Zellweger T, Maurer R, Alund G, Knonagel H, Rist M, Jordan P, Moch H, Mihatsch MJ, Gasser TC, Sauter G. Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer. *J Pathol* 1999; 188(1):44-50.
 51. Wallmeroth A, Wagner U, Moch H, Gasser TC, Sauter G, Mihatsch MJ. Patterns of metastasis in muscle-invasive bladder cancer (pT2-4): An autopsy study on 367 patients. *Urol Int* 1999; 62(2):69-75.

52. Zhao J, Richter J, Wagner U, Roth B, Schraml P, Zellweger T, Ackermann D, Schmid U, Moch H, Mihatsch MJ, Gasser TC, Sauter G. Chromosomal imbalances in noninvasive papillary bladder neoplasms (pTa). *Cancer Res* 1999; 59(18):4658-61.
53. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. *Hum Pathol* 2000; 31(5):578-83.
54. Desper R, Jiang F, Kallioniemi OP, Moch H, Papadimitriou CH, Schaffer AA. Distance-based reconstruction of tree models for oncogenesis. *J Comput Biol* 2000; 7(6):789-803.
55. Fu W, Bubendorf L, Willi N, Moch H, Mihatsch MJ, Sauter G, Gasser TC. Genetic changes in clinically organ-confined prostate cancer by comparative genomic hybridization. *Urology* 2000; 56(5):880-5.
56. Jiang F, Desper R, Papadimitriou CH, Schaffer AA, Kallioniemi OP, Richter J, Schraml P, Sauter G, Mihatsch MJ, Moch H. Construction of evolutionary tree models for renal cell carcinoma from comparative genomic hybridization data. *Cancer Res* 2000; 60(22):6503-9.
57. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. *Cancer* 2000; 89(3):604-14.
58. Richter J, Wagner U, Kononen J, Fijan A, Bruderer J, Schmid U, Ackermann D, Maurer R, Alund G, Knonagel H, Rist M, Wilber K, Anabitarte M, Hering F, Hardmeier T, Schonenberger A, Flury R, Jager P, Fehr JL, Schraml P, Moch H, Mihatsch MJ, Gasser T, Kallioniemi OP, Sauter G. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. *Am J Pathol* 2000; 157(3):787-94.
59. Schraml P, Muller D, Bednar R, Gasser T, Sauter G, Mihatsch MJ, Moch H. Allelic loss at the D9S171 locus on chromosome 9p13 is associated with progression of papillary renal cell carcinoma. *J Pathol* 2000; 190(4):457-61.
60. Terracciano LM, Mhawech P, Suess K, D'Armiento M, Lehmann FS, Jundt G, Moch H, Sauter G, Mihatsch MJ. Calretinin as a marker for cardiac myxoma. Diagnostic and histogenetic considerations. *Am J Clin Pathol* 2000; 114(5):754-9.
61. Tornillo L, Carafa V, Richter J, Sauter G, Moch H, Minola E, Gambacorta M, Bianchi L, Vecchione R, Terracciano LM. Marked genetic similarities between hepatitis B virus-positive and hepatitis C virus-positive hepatocellular carcinomas. *J Pathol* 2000; 192(3):307-12.
62. de Peralta-Venturina M, Moch H, Amin M, Tamboli P, Hailemariam S, Mihatsch M, Javidan J, Stricker H, Ro JY, Amin MB. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. *Am J Surg Pathol* 2001; 25(3):275-84.
63. El Gedaily A, Bubendorf L, Willi N, Fu W, Richter J, Moch H, Mihatsch MJ, Sauter G, Gasser TC. Discovery of new DNA amplification loci in prostate cancer by comparative genomic hybridization. *Prostate* 2001; 46(3):184-90.
64. Isler SG, Schenk S, Bendik I, Schraml P, Novotna H, Moch H, Sauter G, Ludwig CU. Genomic organization and chromosomal mapping of SPARC-like 1, a gene down regulated in cancers. *Int J Oncol* 2001; 18(3):521-6.

65. Morrissey C, Martinez A, Zatyka M, Agathangelou A, Honorio S, Astuti D, Morgan NV, Moch H, Richards FM, Kishida T, Yao M, Schraml P, Latif F, Maher ER. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. *Cancer Res* 2001; 61(19):7277-81.
66. Nocito A, Bubendorf L, Maria Tinner E, Suess K, Wagner U, Forster T, Kononen J, Fijan A, Bruderer J, Schmid U, Ackermann D, Maurer R, Alund G, Knonagel H, Rist M, Anabitarte M, Hering F, Hardmeier T, Schoenenberger AJ, Flury R, Jager P, Luc Fehr J, Schraml P, Moch H, Mihatsch MJ, Gasser T, Sauter G. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. *J Pathol* 2001; 194(3):349-57.
67. Schraml P, Struckmann K, Bednar R, Fu W, Gasser T, Wilber K, Kononen J, Sauter G, Mihatsch MJ, Moch H. CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A. *Am J Pathol* 2001; 158(2):593-601.
68. Simon R, Nocito A, Hubscher T, Bucher C, Torhorst J, Schraml P, Bubendorf L, Mihatsch MM, Moch H, Wilber K, Schotzau A, Kononen J, Sauter G. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. *J Natl Cancer Inst* 2001; 93(15):1141-6.
69. Simon R, Richter J, Wagner U, Fijan A, Bruderer J, Schmid U, Ackermann D, Maurer R, Alund G, Knonagel H, Rist M, Wilber K, Anabitarte M, Hering F, Hardmeier T, Schonberger A, Flury R, Jager P, Fehr JL, Schraml P, Moch H, Mihatsch MJ, Gasser T, Sauter G. High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. *Cancer Res* 2001; 61(11):4514-9.
70. Tomovska S, Richter J, Suess K, Wagner U, Rozenblum E, Gasser TC, Moch H, Mihatsch MJ, Sauter G, Schraml P. Molecular cytogenetic alterations associated with rapid tumor cell proliferation in advanced urinary bladder cancer. *Int J Oncol* 2001; 18(6):1239-44.
71. Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi OP, Sauter G. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. *Am J Pathol* 2001; 159(6):2249-56.
72. Zhao J, Moch H, Scheidweiler AF, Baer A, Schaffer AA, Speel EJ, Roth J, Heitz PU, Komminoth P. Genomic imbalances in the progression of endocrine pancreatic tumors. *Genes Chromosomes Cancer* 2001; 32(4):364-72.
73. Dellas A, Torhorst J, Schultheiss E, Mihatsch MJ, Moch H. DNA sequence losses on chromosomes 11p and 18q are associated with clinical outcome in lymph node-negative ductal breast cancer. *Clin Cancer Res* 2002; 8(5):1210-6.
74. Guller U, Nitzsche EU, Schirp U, Viehl CT, Torhorst J, Moch H, Langer I, Marti WR, Oertli D, Harder F, Zuber M. Selective axillary surgery in breast cancer patients based on positron emission tomography with 18F-fluoro-2-deoxy-D-glucose: not yet! *Breast Cancer Res Treat* 2002; 71(2):171-3.
75. Schraml P, Struckmann K, Hatz F, Sonnet S, Kully C, Gasser T, Sauter G, Mihatsch MJ, Moch H. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. *J Pathol* 2002; 196(2):186-93.
76. Simon R, Struckmann K, Schraml P, Wagner U, Forster T, Moch H, Fijan A, Bruderer J, Wilber K, Mihatsch MJ, Gasser T, Sauter G. Amplification pattern of 12q13-q15

- genes (MDM2, CDK4, GLI) in urinary bladder cancer. *Oncogene* 2002; 21(16):2476-83.
77. Tornillo L, Carafa V, Sauter G, Moch H, Minola E, Gambacorta M, Vecchione R, Bianchi L, Terracciano LM. Chromosomal alterations in hepatocellular nodules by comparative genomic hybridization: high-grade dysplastic nodules represent early stages of hepatocellular carcinoma. *Lab Invest* 2002; 82(5):547-53.
 78. Dellas A, Torhorst J, Gaudenz R, Mihatsch MJ, Moch H. DNA copy number changes in cervical adenocarcinoma. *Clin Cancer Res* 2003; 9(8):2985-91.
 79. Glatzel M, Ott PM, Linder T, Gebbers JO, Gmur A, Wust W, Huber G, Moch H, Podvynec M, Stamm B, Aguzzi A. Human prion diseases: epidemiology and integrated risk assessment. *Lancet Neurol* 2003; 2(12):757-63.
 80. Schraml P, Hergovitz A, Hatz F, Amin MB, Lim SD, Krek W, Mihatsch MJ, Moch H. Relevance of nuclear and cytoplasmic von hippel lindau protein expression for renal carcinoma progression. *Am J Pathol* 2003; 163(3):1013-20.
 81. Schraml P, Schwerdtfeger G, Burkhalter F, Raggi A, Schmidt D, Ruffalo T, King W, Wilber K, Mihatsch MJ, Moch H. Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma. *Am J Pathol* 2003; 163(3):985-92.
 82. Stadlmann S, Pollheimer J, Moser PL, Raggi A, Amberger A, Margreiter R, Offner FA, Mikuz G, Dirnhofer S, Moch H. Cytokine-regulated expression of collagenase-2 (MMP-8) is involved in the progression of ovarian cancer. *Eur J Cancer* 2003; 39(17):2499-505.
 83. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. *Nature* 2003; 425(6955):307-11.
 84. Terracciano LM, Bernasconi B, Ruck P, Stallmach T, Briner J, Sauter G, Moch H, Vecchione R, Pollice L, Pettinato G, Gurtl B, Ratschek M, De Krijger R, Tornillo L, Bruder E. Comparative genomic hybridization analysis of hepatoblastoma reveals high frequency of X-chromosome gains and similarities between epithelial and stromal components. *Hum Pathol* 2003; 34(9):864-71.
 85. Bruder E, Passera O, Harms D, Leuschner I, Ladanyi M, Argani P, Eble JN, Struckmann K, Schraml P, Moch H. Morphologic and molecular characterization of renal cell carcinoma in children and young adults. *Am J Surg Pathol* 2004; 28(9):1117-32.
 86. Dellas A, Puhl A, Schraml P, Thomke SE, Ruschoff J, Mihatsch MJ, Moch H. Molecular and clinicopathological analysis of ovarian carcinomas with and without microsatellite instability. *Anticancer Res* 2004; 24(1):361-9.
 87. Guth U, Moch H, Herberich L, Holzgreve W. Noninflammatory breast carcinoma with skin involvement. *Cancer* 2004; 100(3):470-8.
 88. Haag-Wackernagel D, Moch H. Health hazards posed by feral pigeons. *J Infect* 2004; 48(4):307-13.
 89. Morris MR, Maina E, Morgan NV, Gentle D, Astuti D, Moch H, Kishida T, Yao M, Schraml P, Richards FM, Latif F, Maher ER. Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumour suppressor genes in renal cell carcinoma. *J Clin Pathol* 2004; 57(7):706-11.

90. Singer G, Kallinowski T, Hartmann A, Dietmaier W, Wild PJ, Schraml P, Sauter G, Mihatsch MJ, Moch H. Different types of microsatellite instability in ovarian carcinoma. *Int J Cancer* 2004; 112(4):643.
91. Struckmann K, Schraml P, Simon R, Elmenhorst K, Mirlacher M, Kononen J, Moch H. Impaired expression of the cell cycle regulator BTG2 is common in clear cell renal cell carcinoma. *Cancer Res* 2004; 64(5):1632-8.
92. Tornillo L, Moch H, Diener PA, Lugli A, Singer G. CDX-2 immunostaining in primary and secondary ovarian carcinomas. *J Clin Pathol* 2004; 57(6):641-3.
93. Zheng M, Simon R, Kononen J, Sauter G, Mihatsch MJ, Moch H. [Analysis of gene expression profiles among 3 epithelial ovarian tumor subtypes using cDNA and tissue microarrays]. *Chinese Journal of Cancer* 2004; 23(7):771-6.
94. Langer I, Marti WR, Guller U, Moch H, Harder F, Oertli D, Zuber M. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy. *Ann Surg* 2005; 241(1):152-8.
95. Lardinois D, Weder W, Roudas M, von Schulthess GK, Tutic M, Moch H, Stahel RA, Steinert HC. Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer. *J Clin Oncol* 2005; 23(28):6846-53.
96. Mazon Pelaez I, Vogler S, Strauss U, Wernhoff P, Pahnke J, Brockmann G, Moch H, Thiesen HJ, Rolfs A, Ibrahim SM. Identification of quantitative trait loci controlling cortical motor evoked potentials in experimental autoimmune encephalomyelitis: correlation with incidence, onset and severity of disease. *Hum Mol Genet* 2005; 14(14):1977-89.
97. Weber WP, Zanetti R, Langer I, Dellas S, Zuber M, Moch H, Rimmeler E, Oertli D, Wight E, Marti WR. Mammotome: less invasive than ABBI with similar accuracy for early breast cancer detection. *World J Surg* 2005; 29(4):495-9.
98. Went P, Dirnhofer S, Salvisberg T, Amin MB, Lim SD, Diener PA, Moch H. Expression of epithelial cell adhesion molecule (EpCam) in renal epithelial tumors. *Am J Surg Pathol* 2005; 29(1):83-8.
99. Bode B, Frigerio S, Behnke S, Senn B, Odermatt B, Zimmermann DR, Moch H. Mutations in the tyrosine kinase domain of the EGFR gene are rare in synovial sarcoma. *Mod Pathol* 2006; 19(4):541-7.
100. Mihic-Probst D, Mních CD, Oberholzer PA, Seifert B, Sasse B, Moch H, Dummer R. p16 expression in primary malignant melanoma is associated with prognosis and lymph node status. *Int J Cancer* 2006; 118(9):2262-8.
101. Reineke T, Jenni B, Abdou MT, Frigerio S, Zubler P, Moch H, Tinguely M. Ultrasonic decalcification offers new perspectives for rapid FISH, DNA, and RT-PCR analysis in bone marrow trephines. *Am J Surg Pathol* 2006; 30(7):892-6.
102. Spizzo G, Went P, Dirnhofer S, Obrist P, Moch H, Baeuerle PA, Mueller-Holzner E, Marth C, Gastl G, Zeimet AG. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. *Gynecol Oncol* 2006; 103(2):483-8.
103. Tickoo SK, Deperalta-Venturina MN, Harik LR, Worcester HD, Salama ME, Young AN, Moch H, Amin MB. Spectrum of Epithelial Neoplasms in End-Stage Renal Disease: An Experience From 66 Tumor-Bearing Kidneys With Emphasis on

- Histologic Patterns Distinct From Those in Sporadic Adult Renal Neoplasia. *Am J Surg Pathol* 2006; 30(2):141-53.
104. Varga Z, Theurillat JP, Filonenko V, Sasse B, Odermatt B, Jungbluth AA, Chen YT, Old LJ, Knuth A, Jager D, Moch H. Preferential nuclear and cytoplasmic NY-BR-1 protein expression in primary breast cancer and lymph node metastases. *Clin Cancer Res* 2006; 12(9):2745-51.
 105. Vogler S, Pahnke J, Rousset S, Ricquier D, Moch H, Miroux B, Ibrahim SM. Uncoupling protein 2 has protective function during experimental autoimmune encephalomyelitis. *Am J Pathol* 2006; 168(5):1570-5.
 106. Argani P, Olgac S, Tickoo SK, Goldfischer M, Moch H, Chan DY, Eble JN, Bonsib SM, Jimeno M, Lloreta J, Billis A, Hicks J, De Marzo AM, Reuter VE, Ladanyi M. Xp11 Translocation Renal Cell Carcinoma in Adults: Expanded Clinical, Pathologic, and Genetic Spectrum. *Am J Surg Pathol* 2007; 31(8):1149-60.
 107. Bode-Lesniewska B, Frigerio S, Exner U, Abdou MT, Moch H, Zimmermann DR. Relevance of translocation type in myxoid liposarcoma and identification of a novel EWSR1-DDIT3 fusion. *Genes Chromosomes Cancer* 2007; 46(11):961-71.
 108. Bruder E, Moch H, Ehrlich D, Leuschner I, Harms D, Argani P, Briner J, Graf N, Selle B, Ruffle A, Paulussen M, Koesters R. Wnt signaling pathway analysis in renal cell carcinoma in young patients. *Mod Pathol* 2007; 20(12):1217-29.
 109. Ceschi M, Gutzwiller F, Moch H, Eichholzer M, Probst-Hensch N. Epidemiology and pathophysiology of obesity as cause of cancer. *Swiss Med Wkly* 2007; 137(3-4):50-6.
 110. Dietel M, Ellis IO, Hofler H, Kreipe H, Moch H, Dankof A, Kolble K, Kristiansen G. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. *Virchows Arch* 2007; 451(1):19-25.
 111. Frigerio S, Padberg BC, Strebel RT, Lenggenhager DM, Messthaler A, Abdou MT, Moch H, Zimmermann DR. Improved detection of bladder carcinoma cells in voided urine by standardized microsatellite analysis. *Int J Cancer* 2007; 121(2):329-38.
 112. Hinterberger M, Reineke T, Storz M, Weder W, Vogt P, Moch H. D2-40 and calretinin-a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation. *Mod Pathol* 2007; 20(2):248-55.
 113. Huber LC, Brock M, Hemmatzad H, Giger OT, Moritz F, Trenkmann M, Distler JH, Gay RE, Kolling C, Moch H, Michel BA, Gay S, Distler O, Jungel A. Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients. *Arthritis Rheum* 2007; 56(4):1087-93.
 114. Jager D, Filonenko V, Gout I, Frosina D, Eastlake-Wade S, Castelli S, Varga Z, Moch H, Chen YT, Busam KJ, Seil I, Old LJ, Nissan A, Frei C, Gure AO, Knuth A, Jungbluth AA. NY-BR-1 is a differentiation antigen of the mammary gland. *Appl Immunohistochem Mol Morphol* 2007; 15(1):77-83.
 115. Mertz KD, Demichelis F, Kim R, Schraml P, Storz M, Diener PA, Moch H, Rubin MA. Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer. *Hum Pathol* 2007; 38(10):1454-62.
 116. Mihic-Probst D, Kuster A, Kilgus S, Bode-Lesniewska B, Ingold-Heppner B, Leung C, Storz M, Seifert B, Marino S, Schraml P, Dummer R, Moch H. Consistent

- expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma. *Int J Cancer* 2007; 121(8):1764-70.
117. Schmid S, Opravil M, Moddel M, Huber M, Pfammatter R, Keusch G, Ambuhl P, Wuthrich RP, Moch H, Varga Z. Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies. *Virchows Arch* 2007; 450(6):665-70.
 118. Schmitt AM, Anlauf M, Rousson V, Schmid S, Kofler A, Riniker F, Bauersfeld J, Barghorn A, Probst-Hensch NM, Moch H, Heitz PU, Kloepfel G, Komminoth P, Perren A. WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. *Am J Surg Pathol* 2007; 31(11):1677-82.
 119. Stadlmann S, Gueth U, Baumhoer D, Moch H, Terracciano L, Singer G. Glypican-3 Expression in Primary and Recurrent Ovarian Carcinomas. *Int J Gynecol Pathol* 2007; 26(3):341-4.
 120. Theurillat JP, Ingold F, Frei C, Zippelius A, Varga Z, Seifert B, Chen YT, Jager D, Knuth A, Moch H. NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. *Int J Cancer* 2007; 120(11):2411-7.
 121. Theurillat JP, Zurrer-Hardi U, Varga Z, Storz M, Probst-Hensch NM, Seifert B, Fehr MK, Fink D, Ferrone S, Pestalozzi B, Jungbluth AA, Chen YT, Jager D, Knuth A, Moch H. NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy. *Cancer Immunol Immunother* 2007; 56(11):1723-31.
 122. Thoma CR, Frew IJ, Hoerner CR, Montani M, Moch H, Krek W. pVHL and GSK3beta are components of a primary cilium-maintenance signalling network. *Nat Cell Biol* 2007; 9(5):588-95.
 123. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majumdar K, Ziaugra L, Wong KK, Gabriel S, Beroukhi R, Peyton M, Barretina J, Dutt A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, Garraway LA. High-throughput oncogene mutation profiling in human cancer. *Nat Genet* 2007; 39(3):347-51.
 124. Tinguely M, Jenni B, Reineke T, Korol D, Kofler A, Rousson V, Dommann-Scherrer C, Maurer R, Moch H, Probst-Hensch NM. Chromosomal Translocations t(4;14), t(11;14) and Proliferation Rate Stratify Patients With Mature Plasma Cell Myelomas Into Groups With Different Survival Probabilities-A Molecular Epidemiologic Study on Tissue Microarrays. *Am J Surg Pathol* 2007; 31(5):690-6.
 125. Zhao J, Yart A, Frigerio S, Perren A, Schraml P, Weisstanner C, Stallmach T, Krek W, Moch H. Sporadic human renal tumors display frequent allelic imbalances and novel mutations of the HRPT2 gene. *Oncogene* 2007; 26(23):3440-9.
 126. Ziegler A, Seemayer CA, Hinterberger M, Vogt P, Bigosch C, Gautschi O, Tornillo L, Betticher DC, Moch H, Stahel RA. Low prevalence of SV40 in Swiss mesothelioma patients after elimination of false-positive PCR results. *Lung Cancer* 2007; 57(3):282-91.
 127. Zippelius A, Gati A, Bartnick T, Walton S, Odermatt B, Jaeger E, Dummer R, Urosevic M, Filonenko V, Osanai K, Moch H, Chen YT, Old LJ, Knuth A, Jaeger D.

- Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients. *Cancer Immunol Immunother* 2007; 56(2):249-58.
128. Amin MB, Paner GP, Alvarado-Cabrero I, Young AN, Stricker HJ, Lyles RH, Moch H. Chromophobe Renal Cell Carcinoma: Histomorphologic Characteristics and Evaluation of Conventional Pathologic Prognostic Parameters in 145 Cases. *Am J Surg Pathol* 2008; 32(12):1822-34.
 129. Curioni-Fontecedro A, Knights AJ, Tinguely M, Nuber N, Schneider C, Thomson CW, von Boehmer L, Bossart W, Pahlich S, Gehring H, Moch H, Renner C, Knuth A, Zippelius A. MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma. *Leukemia* 2008; 22(8):1646-8.
 130. Frew IJ, Minola A, Georgiev S, Hitz M, Moch H, Richard S, Vortmeyer AO, Krek W. Combined VHLH and PTEN mutation causes genital tract cystadenoma and squamous metaplasia. *Mol Cell Biol* 2008; 28(14):4536-48.
 131. Frew IJ, Thoma CR, Georgiev S, Minola A, Hitz M, Montani M, Moch H, Krek W. pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. *Embo J* 2008; 27(12):1747-57.
 132. Fritzsche FR, Oelrich B, Johannsen M, Kristiansen I, Moch H, Jung K, Kristiansen G. Claudin-1 protein expression is a prognostic marker of patient survival in renal cell carcinomas. *Clin Cancer Res* 2008; 14(21):7035-42.
 133. Fritzsche FR, Riener MO, Dietel M, Moch H, Jung K, Kristiansen G. GOLPH2 expression in renal cell cancer. *BMC Urol* 2008; 8(1):15.
 134. Fuchs TJ, Wild PJ, Moch H, Buhmann JM. Computational pathology analysis of tissue microarrays predicts survival of renal clear cell carcinoma patients. *Med Image Comput Comput Assist Interv Int Conf Med Image Comput Comput Assist Interv* 2008; 11(Pt 2):1-8.
 135. Garbrecht N, Anlauf M, Schmitt A, Henopp T, Sipos B, Raffel A, Eisenberger CF, Knoefel WT, Pavel M, Fottner C, Musholt TJ, Rinke A, Arnold R, Berndt U, Plockinger U, Wiedenmann B, Moch H, Heitz PU, Komminoth P, Perren A, Kloppel G. Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. *Endocr Relat Cancer* 2008; 15(1):229-41.
 136. Ingold B, Wild PJ, Nocito A, Amin MB, Storz M, Heppner FL, Moch H. Renal cell carcinoma marker reliably discriminates central nervous system haemangioblastoma from brain metastases of renal cell carcinoma. *Histopathology* 2008; 52(6):674-81.
 137. Kristiansen G, Fritzsche FR, Wassermann K, Jager C, Tolle A, Lein M, Stephan C, Jung K, Pilarsky C, Dietel M, Moch H. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. *Br J Cancer* 2008; 99(6):939-48.
 138. Lebeau A, Grob T, Holst F, Seyedi-Fazlollahi N, Moch H, Terracciano L, Turzynski A, Choschzick M, Sauter G, Simon R. Oestrogen receptor gene (ESR1) amplification is frequent in endometrial carcinoma and its precursor lesions. *J Pathol* 2008; 216(2):151-7.
 139. Mertz KD, Demichelis F, Sboner A, Hirsch MS, Dal Cin P, Struckmann K, Storz M, Scherrer S, Schmid DM, Strebel RT, Probst-Hensch NM, Gerstein M, Moch H, Rubin

- MA. Association of cytokeratin 7 and 19 expression with genomic stability and favorable prognosis in clear cell renal cell cancer. *Int J Cancer* 2008; 123(3):569-76.
140. Opitz I, Soltermann A, Abaecherli M, Hinterberger M, Probst-Hensch N, Stahel R, Moch H, Weder W. PTEN expression is a strong predictor of survival in mesothelioma patients. *Eur J Cardiothorac Surg* 2008; 33(3):502-6.
141. Perner S, Wagner PL, Demichelis F, Mehra R, Lafargue CJ, Moss BJ, Arbogast S, Soltermann A, Weder W, Giordano TJ, Beer DG, Rickman DS, Chinnaiyan AM, Moch H, Rubin MA. EML4-ALK fusion lung cancer: a rare acquired event. *Neoplasia* 2008; 10(3):298-302.
142. Reschke M, Mihic-Probst D, van der Horst EH, Knyazev P, Wild PJ, Hutterer M, Meyer S, Dummer R, Moch H, Ullrich A. HER3 is a determinant for poor prognosis in melanoma. *Clin Cancer Res* 2008; 14(16):5188-97.
143. Schmitt AM, Riniker F, Anlauf M, Schmid S, Soltermann A, Moch H, Heitz PU, Kloppel G, Komminoth P, Perren A. Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases. *Am J Surg Pathol* 2008; 32(3):420-5.
144. Soltermann A, Ossola R, Kilgus-Hawelski S, von Eckardstein A, Suter T, Aebersold R, Moch H. N-glycoprotein profiling of lung adenocarcinoma pleural effusions by shotgun proteomics. *Cancer* 2008; 114(2):124-33.
145. Soltermann A, Tischler V, Arbogast S, Braun J, Probst-Hensch N, Weder W, Moch H, Kristiansen G. Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. *Clin Cancer Res* 2008; 14(22):7430-7.
146. Steu S, Baucamp M, von Dach G, Bawohl M, Dettwiler S, Storz M, Moch H, Schraml P. A procedure for tissue freezing and processing applicable to both intra-operative frozen section diagnosis and tissue banking in surgical pathology. *Virchows Arch* 2008; 452(3):305-12.
147. Struckmann K, Mertz K, Steu S, Storz M, Staller P, Krek W, Schraml P, Moch H. pVHL co-ordinately regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell renal cell carcinoma. *J Pathol* 2008; 214(4):464-71.
148. Theurillat JP, Zurrer-Hardi U, Varga Z, Barghorn A, Saller E, Frei C, Storz M, Behnke S, Seifert B, Fehr M, Fink D, Rageth C, Linsenmeier C, Pestalozzi B, Chen YT, Knuth A, Jager D, Moch H. Distinct expression patterns of the immunogenic differentiation antigen NY-BR-1 in normal breast, testis and their malignant counterparts. *Int J Cancer* 2008; 122(7):1585-91.
149. Tinguely M, Jenni B, Knights A, Lopes B, Korol D, Rousson V, Curioni Fontecedro A, Cogliatti SB, Bittermann AG, Schmid U, Dommann-Scherrer C, Maurer R, Renner C, Probst-Hensch NM, Moch H, Knuth A, Zippelius A. MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome. *Cancer Sci* 2008; 99(4):720-5.
150. Varga Z, Rageth C, Saurenmann E, Honegger C, von Orelli S, Fehr M, Fink D, Seifert B, Moch H, Caduff R. Use of intraoperative stereomicroscopy for preventing loss of metastases during frozen sectioning of sentinel lymph nodes in breast cancer. *Histopathology* 2008; 52(5):597-604.
151. Vasei M, Moch H, Mousavi A, Kajbafzadeh AM, Sauter G. Immunohistochemical profiling of Wilms tumor: a tissue microarray study. *Appl Immunohistochem Mol Morphol* 2008; 16(2):128-34.

152. Waibel R, Treichler H, Schaefer NG, van Staveren DR, Mundwiler S, Kunze S, Kuenzi M, Alberto R, Nuesch J, Knuth A, Moch H, Schibli R, Schubiger PA. New derivatives of vitamin B12 show preferential targeting of tumors. *Cancer Res* 2008; 68(8):2904-11.
153. Weber A, Kristiansen I, Johannsen M, Oelrich B, Scholmann K, Gunia S, May M, Meyer HA, Behnke S, Moch H, Kristiansen G. The FUSE binding proteins FBP1 and FBP3 are potential c-myc regulators in renal, but not in prostate and bladder cancer. *BMC Cancer* 2008; 8(1):369.
154. Zhao J, Leonard C, Gemenjager E, Heitz PU, Moch H, Odermatt B. Differentiation of human follicular thyroid adenomas from carcinomas by gene expression profiling. *Oncol Rep* 2008; 19(2):329-37.
155. Zhao J, Moch H. Absence of JH2 domain mutation of the tyrosine kinase JAK2 in renal cell carcinomas. *Acta Oncol* 2008; 47(3):474-6.
156. Anlauf M, Bauersfeld J, Raffel A, Koch CA, Henopp T, Alkatout I, Schmitt A, Weber A, Kruse ML, Braunstein S, Kaserer K, Brauckhoff M, Dralle H, Moch H, Heitz PU, Komminoth P, Knoefel WT, Perren A, Kloppel G. Insulinomatosis: a multicentric insulinoma disease that frequently causes early recurrent hyperinsulinemic hypoglycemia. *Am J Surg Pathol* 2009; 33(3):339-46.
157. Balamurugan K, Luu VD, Kaufmann MR, Hofmann VS, Boysen G, Barth S, Bordoli MR, Stiehl DP, Moch H, Schraml P, Wenger RH, Camenisch G. Onconeural cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response. *Oncogene* 2009; 28(37):3274-85.
158. Beroukhi R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, Pires MM, Linhart D, Worrell RA, Moch H, Rubin MA, Sellers WR, Meyerson M, Linehan WM, Kaelin WG, Jr., Signoretti S. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. *Cancer Res* 2009; 69(11):4674-81.
159. Dellas A, Jundt G, Sartorius G, Schneider M, Moch H. Combined PTEN and p27kip1 protein expression patterns are associated with obesity and prognosis in endometrial carcinomas. *Clin Cancer Res* 2009; 15(7):2456-62.
160. Gerstung M, Baudis M, Moch H, Beerenwinkel N. Quantifying cancer progression with conjunctive Bayesian networks. *Bioinformatics* 2009; 25(21):2809-15.
161. Ghadjar P, Blank-Liss W, Simcock M, Hegyi I, Beer KT, Moch H, Aebbersold DM, Zimmer Y. MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers. *Clin Exp Metastasis* 2009; 26(7):809-15.
162. Gutwein P, Schramme A, Voss B, Abdel-Bakky MS, Doberstein K, Ludwig A, Altevogt P, Hansmann ML, Moch H, Kristiansen G, Pfeilschifter J. Downregulation of junctional adhesion molecule-A is involved in the progression of clear cell renal cell carcinoma. *Biochem Biophys Res Commun* 2009; 380(2):387-91.
163. Ingold B, Schraml P, Heppner FL, Moch H. Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors. *PLoS ONE* 2009; 4(3):e4775.

164. Issa RM, Lebeau A, Grob T, Holst F, Moch H, Terracciano L, Choschzick M, Sauter G, Simon R. Estrogen receptor gene amplification occurs rarely in ovarian cancer. *Mod Pathol* 2009; 22(2):191-6.
165. Kellner A, Matschke J, Bernreuther C, Moch H, Ferrer I, Glatzel M. Autoantibodies against beta-amyloid are common in Alzheimer's disease and help control plaque burden. *Ann Neurol* 2009; 65(1):24-31.
166. Kempkensteffen C, Fritzsche FR, Johannsen M, Weikert S, Hinz S, Dietel M, Riener MO, Moch H, Jung K, Krause H, Miller K, Kristiansen G. Down-regulation of the pro-apoptotic XIAP associated factor-1 (XAF1) during progression of clear-cell renal cancer. *BMC Cancer* 2009; 9:276.
167. Langer I, Guller U, Berclaz G, Koechli OR, Moch H, Schaer G, Fehr MK, Hess T, Oertli D, Bronz L, Schnarwyler B, Wight E, Uehlinger U, Infanger E, Burger D, Zuber M. Accuracy of frozen section of sentinel lymph nodes: a prospective analysis of 659 breast cancer patients of the Swiss multicenter study. *Breast Cancer Res Treat* 2009; 113(1):129-36.
168. Langer I, Guller U, Hsu-Schmitz SF, Ladewig A, Viehl CT, Moch H, Wight E, Harder F, Oertli D, Zuber M. Sentinel lymph node biopsy is associated with improved survival compared to level I & II axillary lymph node dissection in node negative breast cancer patients. *Eur J Surg Oncol* 2009; 35(8):805-13.
169. Langer I, Guller U, Viehl CT, Moch H, Wight E, Harder F, Oertli D, Zuber M. Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study. *Ann Surg Oncol* 2009; 16(12):3366-74.
170. Luu VD, Boysen G, Struckmann K, Casagrande S, von Teichman A, Wild PJ, Sulser T, Schraml P, Moch H. Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma. *Clin Cancer Res* 2009; 15(10):3297-304.
171. Perner S, Wagner PL, Soltermann A, LaFargue C, Tischler V, Weir BA, Weder W, Meyerson M, Giordano TJ, Moch H, Rubin MA. TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival. *J Pathol* 2009; 217(1):65-72.
172. Riener MO, Stenner F, Liewen H, Soll C, Breitenstein S, Pestalozzi BC, Samaras P, Probst-Hensch N, Hellerbrand C, Mullhaupt B, Clavien PA, Bahra M, Neuhaus P, Wild P, Fritzsche F, Moch H, Jochum W, Kristiansen G. Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. *Hepatology* 2009; 49(5):1602-9.
173. Riener MO, Wild PJ, Soll C, Knuth A, Jin B, Jungbluth A, Hellerbrand C, Clavien PA, Moch H, Jochum W. Frequent expression of the novel cancer testis antigen MAGE-C2/CT-10 in hepatocellular carcinoma. *Int J Cancer* 2009; 124(2):352-7.
174. Schmitt AM, Schmid S, Rudolph T, Anlauf M, Prinz C, Kloppel G, Moch H, Heitz PU, Komminoth P, Perren A. VHL inactivation is an important pathway for the development of malignant sporadic pancreatic endocrine tumors. *Endocr Relat Cancer* 2009; 16(4):1219-27.
175. Schraml P, Frew IJ, Thoma CR, Boysen G, Struckmann K, Krek W, Moch H. Sporadic clear cell renal cell carcinoma but not the papillary type is characterized by severely reduced frequency of primary cilia. *Mod Pathol* 2009; 22(1):31-6.
176. Sconocchia G, Spagnoli GC, Del Principe D, Ferrone S, Anselmi M, Wongsena W, Cervelli V, Schultz-Thater E, Wyler S, Carafa V, Moch H, Terracciano L, Tornillo L.

- Defective infiltration of natural killer cells in MICA/B-positive renal cell carcinoma involves beta(2)-integrin-mediated interaction. *Neoplasia* 2009; 11(7):662-71.
177. Sorensen KD, Wild PJ, Mortezaei A, Adolf K, Topping N, Heeboll S, Ulhoi BP, Ottosen P, Sulser T, Hermanns T, Moch H, Borre M, Orntoft TF, Dyrskjot L. Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy. *Clin Cancer Res* 2009; 15(4):1400-10.
 178. Thoma CR, Toso A, Gutbrodt KL, Reggi SP, Frew IJ, Schraml P, Hergovich A, Moch H, Meraldi P, Krek W. VHL loss causes spindle misorientation and chromosome instability. *Nat Cell Biol* 2009; 11(8):994-1001.
 179. Tolle A, Jung M, Lein M, Johannsen M, Miller K, Moch H, Jung K, Kristiansen G. Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer? *BMC Cancer* 2009; 9:248.
 180. Vasei M, Modjtahedi H, Ale-Booyeh O, Mosallaei A, Kajbafzadeh AM, Shahriari M, Ghaderi AA, Soleymanpour H, Kosari F, Moch H, Sauter G. Amplification and expression of EGFR and ERBB2 in Wilms tumor. *Cancer Genet Cytogenet* 2009; 194(2):88-95.
 181. Wild PJ, Fuchs T, Stoehr R, Zimmermann D, Frigerio S, Padberg B, Steiner I, Zwarthoff EC, Burger M, Denzinger S, Hofstaedter F, Kristiansen G, Hermanns T, Seifert HH, Provenzano M, Sulser T, Roth V, Buhmann JM, Moch H, Hartmann A. Detection of urothelial bladder cancer cells in voided urine can be improved by a combination of cytology and standardized microsatellite analysis. *Cancer Epidemiol Biomarkers Prev* 2009; 18(6):1798-806.
 182. Zellweger T, Gunther S, Zlobec I, Savic S, Sauter G, Moch H, Mattarelli G, Eichenberger T, Curschellas E, Rufenacht H, Bachmann A, Gasser TC, Mihatsch MJ, Bubendorf L. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. *Int J Cancer* 2009; 124(9):2116-23.
 183. Albinger-Hegyí A, Stoeckli SJ, Schmid S, Storz M, Iotzova G, Probst-Hensch NM, Rehrauer H, Tinguely M, Moch H, Hegyi I. Lysyl oxidase expression is an independent marker of prognosis and a predictor of lymph node metastasis in oral and oropharyngeal squamous cell carcinoma (OSCC). *International journal of cancer Journal international du cancer* 2010; 126(11):2653-62.
 184. Blank PR, Schwenkglenks M, Moch H, Szucs TD. Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies. *Breast cancer research and treatment* 2010; 124(2):497-507.
 185. Cueni LN, Hegyi I, Shin JW, Albinger-Hegyí A, Gruber S, Kunstfeld R, Moch H, Detmar M. Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin. *The American journal of pathology* 2010; 177(2):1004-16.
 186. Dahinden C, Ingold B, Wild P, Boysen G, Luu VD, Montani M, Kristiansen G, Sulser T, Buhlmann P, Moch H, Schraml P. Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2010; 16(1):88-98.
 187. Fritzsche FR, Bode PK, Moch H, Kristiansen G, Varga Z, Bode B. Determination of the Her-2/neu gene amplification status in cytologic breast cancer specimens using

- automated silver-enhanced in-situ hybridization (SISH). *The American journal of surgical pathology* 2010; 34(8):1180-5.
188. Fritzsche FR, Reineke T, Morawietz L, Kristiansen G, Dietel M, Fink D, Rageth C, Honegger C, Caduff R, Moch H, Varga Z. Pathological processing techniques and final diagnosis of breast cancer sentinel lymph nodes. *Annals of surgical oncology* 2010; 17(11):2892-8.
 189. Giger O, Caduff R, O'Meara A, Diener PA, Knuth A, Jager D, Moch H, Varga Z. Frequent expression of the breast differentiation antigen NY-BR-1 in mammary and extramammary Paget's disease. *Pathology international* 2010; 60(11):726-34.
 190. Ikenberg K, Fritzsche FR, Zuerrer-Haerdi U, Hofmann I, Hermanns T, Seifert H, Muntener M, Provenzano M, Sulser T, Behnke S, Gerhardt J, Mortezavi A, Wild P, Hofstadter F, Burger M, Moch H, Kristiansen G. Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores. *BMC Cancer* 2010; 10:341.
 191. Kristiansen G, Rose M, Geisler C, Fritzsche FR, Gerhardt J, Luke C, Ladhoff AM, Knuchel R, Dietel M, Moch H, Varga Z, Theurillat JP, Gorr TA, Dahl E. Endogenous myoglobin in human breast cancer is a hallmark of luminal cancer phenotype. *British journal of cancer* 2010; 102(12):1736-45.
 192. Leuenberger M, Frigerio S, Wild PJ, Noetzli F, Korol D, Zimmermann DR, Gengler C, Probst-Hensch NM, Moch H, Tinguely M. AID protein expression in chronic lymphocytic leukemia/small lymphocytic lymphoma is associated with poor prognosis and complex genetic alterations. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc* 2010; 23(2):177-86.
 193. Montani M, Heinimann K, von Teichman A, Rudolph T, Perren A, Moch H. VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease. *The American journal of surgical pathology* 2010; 34(6):806-15.
 194. Nilsson KP, Ikenberg K, Aslund A, Fransson S, Konradsson P, Rocken C, Moch H, Aguzzi A. Structural typing of systemic amyloidoses by luminescent-conjugated polymer spectroscopy. *The American journal of pathology* 2010; 176(2):563-74.
 195. Nuber N, Curioni-Fontecedro A, Matter C, Soldini D, Tiercy JM, von Boehmer L, Moch H, Dummer R, Knuth A, van den Broek M. Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients. *Proceedings of the National Academy of Sciences of the United States of America* 2010; 107(34):15187-92.
 196. Paner GP, Amin MB, Alvarado-Cabrero I, Young AN, Stricker HJ, Moch H, Lyles RH. A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade. *The American journal of surgical pathology* 2010; 34(9):1233-40.
 197. Probst-Hensch NM, Steiner JH, Schraml P, Varga Z, Zurrer-Hardi U, Storz M, Korol D, Fehr MK, Fink D, Pestalozzi BC, Lutolf UM, Theurillat JP, Moch H. IGFBP2 and IGFBP3 protein expressions in human breast cancer: association with hormonal factors and obesity. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2010; 16(3):1025-32.
 198. Riener MO, Fritzsche FR, Soll C, Pestalozzi BC, Probst-Hensch N, Clavien PA, Jochum W, Soltermann A, Moch H, Kristiansen G. Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas. *Histopathology* 2010; 56(5):600-6.

199. Schramm A, Opitz I, Thies S, Seifert B, Moch H, Weder W, Soltermann A. Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma. *European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery* 2010; 37(3):566-72.
200. Studer AM, Limbach LK, Van Duc L, Krumeich F, Athanassiou EK, Gerber LC, Moch H, Stark WJ. Nanoparticle cytotoxicity depends on intracellular solubility: comparison of stabilized copper metal and degradable copper oxide nanoparticles. *Toxicology letters* 2010; 197(3):169-74.
201. Sutter R, Shakhova O, Bhagat H, Behesti H, Sutter C, Penkar S, Santuccione A, Bernays R, Heppner FL, Schuller U, Grotzer M, Moch H, Schraml P, Marino S. Cerebellar stem cells act as medulloblastoma-initiating cells in a mouse model and a neural stem cell signature characterizes a subset of human medulloblastomas. *Oncogene* 2010; 29(12):1845-56.
202. Teichman AV, Comperat E, Behnke S, Storz M, Moch H, Schraml P. VHL mutations and dysregulation of pVHL- and PTEN-controlled pathways in multilocular cystic renal cell carcinoma. *Mod Pathol* 2010.
203. Theurillat JP, Dreier B, Nagy-Davidescu G, Seifert B, Behnke S, Zurrer-Hardi U, Ingold F, Pluckthun A, Moch H. Designed ankyrin repeat proteins: a novel tool for testing epidermal growth factor receptor 2 expression in breast cancer. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc* 2010; 23(9):1289-97.
204. Tischler V, Fritzsche FR, Gerhardt J, Jager C, Stephan C, Jung K, Dietel M, Moch H, Kristiansen G. Comparison of the diagnostic value of fatty acid synthase (FASN) with alpha-methylacyl-CoA racemase (AMACR) as prostatic cancer tissue marker. *Histopathology* 2010; 56(6):811-5.
205. Tischler V, Fritzsche FR, Wild PJ, Stephan C, Seifert HH, Riener MO, Hermanns T, Mortezaei A, Gerhardt J, Schraml P, Jung K, Moch H, Soltermann A, Kristiansen G. Periostin is up-regulated in high grade and high stage prostate cancer. *BMC Cancer* 2010; 10:273.
206. Walter A, Barysch MJ, Behnke S, Dziunycz P, Schmid B, Ritter E, Gnjatic S, Kristiansen G, Moch H, Knuth A, Dummer R, van den Broek M. Cancer-testis antigens and immunosurveillance in human cutaneous squamous cell and basal cell carcinomas. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2010; 16(14):3562-70.
207. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, Heynck S, Koker M, Schottle J, Leenders F, Gabler F, Dabow I, Querings S, Heukamp LC, Balke-Want H, Ansen S, Rauh D, Baessmann I, Altmuller J, Wainer Z, Conron M, Wright G, Russell P, Solomon B, Brambilla E, Brambilla C, Lorimier P, Sollberg S, Brustugun OT, Engel-Riedel W, Ludwig C, Petersen I, Sanger J, Clement J, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman D, Cappuzzo F, Ligorio C, Damiani S, Hallek M, Beroukhi R, Pao W, Klebl B, Baumann M, Buettner R, Ernestus K, Stoelben E, Wolf J, Nurnberg P, Perner S, Thomas RK. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. *Science translational medicine* 2010; 2(62):62ra93.
208. Algaba F, Akaza H, Lopez-Beltran A, Martignoni G, Moch H, Montironi R, Reuter V. Current pathology keys of renal cell carcinoma. *European Urology* 2011; 60(4):634-43.

209. Arbogast S, Behnke S, Opitz I, Stahel RA, Seifert B, Weder W, Moch H, Soltermann A. Automated ERCC1 immunohistochemistry in non-small cell lung cancer: comparison of anti-ERCC1 antibodies 8F1, D-10, and FL-297. *Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry* 2011; 19(2):99-105.
210. Blank PR, Moch H, Szucs TD, Schwenkglenks M. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2011; 17(19):6338-46.
211. Blyszczuk P, Germano D, Stein S, Moch H, Matter CM, Beck-Schimmer B, Luscher TF, Eriksson U, Kania G. Profibrotic potential of prominin-1(+) epithelial progenitor cells in pulmonary fibrosis. *Respir Res* 2011; 12:126.
212. Bode PK, Barghorn A, Fritzsche FR, Riener MO, Kristiansen G, Knuth A, Moch H. MAGEC2 is a sensitive and novel marker for seminoma: a tissue microarray analysis of 325 testicular germ cell tumors. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc* 2011; 24(6):829-35.
213. Brookman-May S, May M, Zigeuner R, Shariat SF, Scherr DS, Chromecki T, Moch H, Wild PJ, Mohamad-Al-Ali B, Cindolo L, Wieland WF, Schips L, De Cobelli O, Rocco B, Santoro L, De Nunzio C, Tubaro A, Coman I, Feciche B, Truss M, Dalpiaz O, Hohenfellner M, Gilfrich C, Wirth MP, Burger M, Pahernik S. Collecting system invasion and Fuhrman grade but not tumor size facilitate prognostic stratification of patients with pT2 renal cell carcinoma. *The Journal of urology* 2011; 186(6):2175-81.
214. Butsch R, Lukas Waelti S, Schaerer S, Braun J, Korol D, Probst-Hensch N, Moch H, Kurrer M. Intratumoral plasmacytoid dendritic cells associate with increased survival in patients with follicular lymphoma. *Leuk Lymphoma* 2011; 52(7):1230-8.
215. Choschzick M, Oosterwijk E, Muller V, Woelber L, Simon R, Moch H, Tennstedt P. Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer. *Virchows Archiv : an international journal of pathology* 2011; 459(2):193-200.
216. Cima I, Schiess R, Wild P, Kaelin M, Schuffler P, Lange V, Picotti P, Ossola R, Templeton A, Schubert O, Fuchs T, Leippold T, Wyler S, Zehetner J, Jochum W, Buhmann J, Cerny T, Moch H, Gillessen S, Aebersold R, Krek W. Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. *Proceedings of the National Academy of Sciences of the United States of America* 2011; 108(8):3342-7.
217. Civenni G, Walter A, Kobert N, Mihic-Probst D, Zipser M, Belloni B, Seifert B, Moch H, Dummer R, van den Broek M, Sommer L. Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. *Cancer research* 2011; 71(8):3098-109.
218. Curioni-Fontecedro A, Nuber N, Mihic-Probst D, Seifert B, Soldini D, Dummer R, Knuth A, van den Broek M, Moch H. Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients. *PLoS ONE* 2011; 6(6):e21418.
219. Dettmer M, Schmitt A, Steinert H, Haldemann A, Meili A, Moch H, Komminoth P, Perren A. Poorly differentiated thyroid carcinomas: how much poorly differentiated is needed? *The American journal of surgical pathology* 2011; 35(12):1866-72.
220. Doberstein K, Wieland A, Lee SB, Blaheta RA, Wedel S, Moch H, Schraml P, Pfeilschifter J, Kristiansen G, Gutwein P. L1-CAM expression in ccRCC correlates

- with shorter patients survival times and confers chemoresistance in renal cell carcinoma cells. *Carcinogenesis* 2011; 32(3):262-70.
221. Fritzsche FR, Hasler A, Bode PK, Adams H, Seifert HH, Sulser T, Moch H, Barghorn A, Kristiansen G. Expression of histone deacetylases 1, 2 and 3 in histological subtypes of testicular germ cell tumours. *Histol Histopathol* 2011; 26(12):1555-61.
 222. Fritzsche FR, Pianca S, Gaspert A, Varga Z, Wang L, Farrell MP, Chen XB, Hirsch HH, Springer E, Fehr T, Myles J, Tubbs R, Moch H. Silver-enhanced in situ hybridization for detection of polyomavirus DNA in patients with BK virus nephropathy. *Diagn Mol Pathol* 2011; 20(2):105-10.
 223. Huber GF, Albinger-Hegyí A, Soltermann A, Roessle M, Graf N, Haerle SK, Holzmann D, Moch H, Hegyí I. Expression patterns of Bmi-1 and p16 significantly correlate with overall, disease-specific, and recurrence-free survival in oropharyngeal squamous cell carcinoma. *Cancer* 2011.
 224. Huber GF, Fritzsche FR, Zullig L, Storz M, Graf N, Haerle SK, Jochum W, Stoeckli SJ, Moch H. Podoplanin expression correlates with sentinel lymph node metastasis in early squamous cell carcinomas of the oral cavity and oropharynx. *International journal of cancer Journal international du cancer* 2011; 129(6):1404-9.
 225. Huber GF, Zullig L, Soltermann A, Roessle M, Graf N, Haerle SK, Studer G, Jochum W, Moch H, Stoeckli SJ. Down regulation of E-Cadherin (ECAD) - a predictor for occult metastatic disease in sentinel node biopsy of early squamous cell carcinomas of the oral cavity and oropharynx. *BMC Cancer* 2011; 11:217:1-8.
 226. Kristiansen G, Hu J, Wichmann D, Stiehl DP, Rose M, Gerhardt J, Bohnert A, Ten Haaf A, Moch H, Raleigh J, Varia MA, Subarsky P, Scandurra FM, Gnaiger E, Gleixner E, Bicker A, Gassmann M, Hankeln T, Dahl E, Gorr TA. Endogenous Myoglobin in Breast Cancer Is Hypoxia-inducible by Alternative Transcription and Functions to Impair Mitochondrial Activity: A ROLE IN TUMOR SUPPRESSION? *The Journal of biological chemistry* 2011; 286(50):43417-28.
 227. Maier S, Wilbertz T, Braun M, Scheble V, Reischl M, Mikut R, Menon R, Nikolov P, Petersen K, Beschorner C, Moch H, Kakies C, Protzel C, Bauer J, Soltermann A, Fend F, Staebler A, Lengerke C, Perner S. SOX2 amplification is a common event in squamous cell carcinomas of different organ sites. *Human pathology* 2011; 42(8):1078-88.
 228. Morra L, Rechsteiner M, Casagrande S, Duc Luu V, Santimaria R, Diener PA, Sulser T, Kristiansen G, Schraml P, Moch H, Soltermann A. Relevance of periostin splice variants in renal cell carcinoma. *The American journal of pathology* 2011; 179(3):1513-21.
 229. Mortezaei A, Hermanns T, Seifert HH, Baumgartner MK, Provenzano M, Sulser T, Burger M, Montani M, Ikenberg K, Hofstadter F, Hartmann A, Jaggi R, Moch H, Kristiansen G, Wild PJ. KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2011; 17(5):1111-21.
 230. Noske A, Zimmermann AK, Caduff R, Varga Z, Fink D, Moch H, Kristiansen G. Alpha-methylacyl-CoA racemase (AMACR) expression in epithelial ovarian cancer. *Virchows Archiv : an international journal of pathology* 2011; 459(1):91-7.
 231. Rechsteiner MP, von Teichman A, Nowicka A, Sulser T, Schraml P, Moch H. VHL gene mutations and their effects on hypoxia inducible factor HIFalpha: identification of potential driver and passenger mutations. *Cancer research* 2011; 71(16):5500-11.

232. Sharma A, Bode B, Wenger RH, Lehmann K, Sartori AA, Moch H, Knuth A, von Boehmer L, van den Broek M. gamma-Radiation Promotes Immunological Recognition of Cancer Cells through Increased Expression of Cancer-Testis Antigens In Vitro and In Vivo. *PLoS ONE* 2011; 6(11):e28217.
233. Soltermann A, Kilgus-Hawelski S, Behnke S, Storz M, Moch H, Bode B. Automated ERCC1 immunochemistry on hybrid cytology/tissue microarray of malignant effusions: evaluation of antibodies 8F1 and D-10. *J Clin Bioinforma* 2011; 1:25.
234. Suwaki N, Vanhecke E, Atkins KM, Graf M, Swabey K, Huang P, Schraml P, Moch H, Cassidy AM, Brewer D, Al-Lazikani B, Workman P, De-Bono J, Kaye SB, Larkin J, Gore ME, Sawyers CL, Nelson P, Beer TM, Geng H, Gao L, Qian DZ, Alumkal JJ, Thomas G, Thomas GV. A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. *Science translational medicine* 2011; 3(85):85ra47.
235. Theurillat JP, Metzler SC, Henzi N, Djouder N, Helbling M, Zimmermann AK, Jacob F, Soltermann A, Caduff R, Heinzelmann-Schwarz V, Moch H, Krek W. URI is an oncogene amplified in ovarian cancer cells and is required for their survival. *Cancer Cell* 2011; 19(3):317-32.
236. Tischler V, Pfeifer M, Hausladen S, Schirmer U, Bonde AK, Kristiansen G, Sos ML, Weder W, Moch H, Altevoigt P, Soltermann A. L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer. *Mol Cancer* 2011; 10:127.
237. Viehl CT, Langer I, Guller U, Zanetti-Dallenbach R, Moch H, Wight E, Oertli D, Zuber M. Prognostic impact and therapeutic implications of sentinel lymph node micro-metastases in early-stage breast cancer patients. *J Surg Oncol* 2011; 103(6):531-3.
238. von Boehmer L, Keller L, Mortezaavi A, Provenzano M, Sais G, Hermanns T, Sulser T, Jungbluth AA, Old LJ, Kristiansen G, van den Broek M, Moch H, Knuth A, Wild PJ. MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer. *PLoS ONE* 2011; 6(7):e21366.
239. von Teichman A, Comperat E, Behnke S, Storz M, Moch H, Schraml P. VHL mutations and dysregulation of pVHL- and PTEN-controlled pathways in multilocular cystic renal cell carcinoma. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc* 2011; 24(4):571-8.
240. Wagner PL, Stiedl AC, Wilbertz T, Petersen K, Scheble V, Menon R, Reischl M, Mikut R, Rubin MA, Fend F, Moch H, Soltermann A, Weder W, Altorki NK, Perner S. Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma. *Lung Cancer* 2011; 74(1):118-23.
241. Walter D, Satheesha S, Albrecht P, Bornhauser BC, D'Alessandro V, Oesch SM, Rehrauer H, Leuschner I, Koscielniak E, Gengler C, Moch H, Bernasconi M, Niggli FK, Schafer BW. CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres. *PLoS ONE* 2011; 6(5):e19506.
242. Wilbertz T, Wagner P, Petersen K, Stiedl AC, Scheble VJ, Maier S, Reischl M, Mikut R, Altorki NK, Moch H, Fend F, Staebler A, Bass AJ, Meyerson M, Rubin MA, Soltermann A, Lengerke C, Perner S. SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc* 2011; 24(7):944-53.

243. Algaba F, Delahunt B, Berney DM, Camparo P, Comperat E, Griffiths D, Kristiansen G, Lopez-Beltran A, Martignoni G, Moch H, Montironi R, Varma M, Egevad L. Handling and reporting of nephrectomy specimens for adult renal tumours: a survey by the European Network of Urothology. *Journal of clinical pathology* 2012; 65(2):106-13.
244. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, Nickerson E, Chae SS, Boysen G, Auclair D, Onofrio RC, Park K, Kitabayashi N, MacDonald TY, Sheikh K, Vuong T, Guiducci C, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Hussain WM, Ramos AH, Winckler W, Redman MC, Ardlie K, Tewari AK, Mosquera JM, Rupp N, Wild PJ, Moch H, Morrissey C, Nelson PS, Kantoff PW, Gabriel SB, Golub TR, Meyerson M, Lander ES, Getz G, Rubin MA, Garraway LA. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. *Nature genetics* 2012; 44(6):685-9.
245. Beleut M, Zimmermann P, Baudis M, Bruni N, Buhlmann P, Laule O, Luu VD, Gruissem W, Schraml P, Moch H. Integrative genome-wide expression profiling identifies three distinct molecular subgroups of renal cell carcinoma with different patient outcome. *BMC Cancer* 2012; 12:310.
246. Boysen G, Bausch-Fluck D, Thoma CR, Nowicka AM, Stiehl DP, Cima I, Luu VD, von Teichman A, Hermanns T, Sulser T, Ingold-Heppner B, Fankhauser N, Wenger RH, Krek W, Schraml P, Wollscheid B, Moch H. Identification and functional characterization of pVHL-dependent cell surface proteins in renal cell carcinoma. *Neoplasia* 2012; 14(6):535-46.
247. Denkert C, Kronenwett R, Schlake W, Bohmann K, Penzel R, Weber KE, Hofler H, Lehmann U, Schirmacher P, Specht K, Rudas M, Kreipe HH, Schraml P, Schlake G, Bago-Horvath Z, Tiecke F, Varga Z, Moch H, Schmidt M, Prinzler J, Kerjaschki D, Sinn BV, Muller BM, Filipits M, Petry C, Dietel M. Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay. *Virchows Archiv : an international journal of pathology* 2012; 460(3):251-9.
248. Dettmer M, Schmitt A, Steinert H, Moch H, Komminoth P, Perren A. Poorly differentiated oncocytic thyroid carcinoma--diagnostic implications and outcome. *Histopathology* 2012; 60(7):1045-51.
249. Gerstung M, Beisel C, Rechsteiner M, Wild P, Schraml P, Moch H, Beerenwinkel N. Reliable detection of subclonal single-nucleotide variants in tumour cell populations. *Nat Commun* 2012; 3:811.
250. Gupta R, Billis A, Shah RB, Moch H, Osunkoya AO, Jochum W, Hes O, Bacchi CE, de Castro MG, Hansel DE, Zhou M, Vankalakunti M, Salles PG, Cabrera RA, Gown AM, Amin MB. Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship. *The American journal of surgical pathology* 2012; 36(9):1265-78.
251. Lehr HA, Moch H, Christen B, Safret A, Gugger M, Rossle M, von Gunten M, Lemoine R, Kurt AM, Caduff R, Walter A, Singer G, Lusciati P, Bannwart F, Genton CY. Board examination for anatomical pathology in Switzerland: two intense days to verify professional competence. *Virchows Archiv : an international journal of pathology* 2012; 461(1):87-92.
252. Meyer S, Fuchs TJ, Bosserhoff AK, Hofstadter F, Pauer A, Roth V, Buhlmann JM, Moll I, Anagnostou N, Brandner JM, Ikenberg K, Moch H, Landthaler M, Vogt T, Wild PJ. A seven-marker signature and clinical outcome in malignant melanoma: a

- large-scale tissue-microarray study with two independent patient cohorts. *PLoS ONE* 2012; 7(6):e38222.
253. Mihic-Probst D, Ikenberg K, Tinguely M, Schraml P, Behnke S, Seifert B, Civenni G, Sommer L, Moch H, Dummer R. Tumor cell plasticity and angiogenesis in human melanomas. *PLoS ONE* 2012; 7(3):e33571.
254. Minner S, Rump D, Tennstedt P, Simon R, Burandt E, Terracciano L, Moch H, Wilczak W, Bokemeyer C, Fisch M, Sauter G, Eichelberg C. Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma. *Cancer* 2012; 118(5):1268-75.
255. Morra L, Rechsteiner M, Casagrande S, von Teichman A, Schraml P, Moch H, Soltermann A. Characterization of periostin isoform pattern in non-small cell lung cancer. *Lung Cancer* 2012; 76(2):183-90.
256. Peifer M, Fernandez-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander T, Menon R, Koker M, Dahmen I, Muller C, Di Cerbo V, Schildhaus HU, Altmuller J, Baessmann I, Becker C, de Wilde B, Vandesompele J, Bohm D, Ansen S, Gabler F, Wilkening I, Heynck S, Heuckmann JM, Lu X, Carter SL, Cibulskis K, Banerji S, Getz G, Park KS, Rauh D, Grutter C, Fischer M, Pasqualucci L, Wright G, Wainer Z, Russell P, Petersen I, Chen Y, Stoelben E, Ludwig C, Schnabel P, Hoffmann H, Muley T, Brockmann M, Engel-Riedel W, Muscarella LA, Fazio VM, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman DA, Snijders PJ, Cappuzzo F, Ligorio C, Damiani S, Field J, Solberg S, Brustugun OT, Lund-Iversen M, Sanger J, Clement JH, Soltermann A, Moch H, Weder W, Solomon B, Soria JC, Validire P, Besse B, Brambilla E, Brambilla C, Lantuejoul S, Lorimier P, Schneider PM, Hallek M, Pao W, Meyerson M, Sage J, Shendure J, Schneider R, Buttner R, Wolf J, Nurnberg P, Perner S, Heukamp LC, Brindle PK, Haas S, Thomas RK. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. *Nature genetics* 2012; 44(10):1104-10.
257. Reiner CS, Goetti R, Eberli D, Klotz E, Boss A, Pfammatter T, Frauenfelder T, Moch H, Sulser T, Alkadhi H. CT perfusion of renal cell carcinoma: impact of volume coverage on quantitative analysis. *Invest Radiol* 2012; 47(1):33-40.
258. Schoenewolf NL, Dummer R, Mihic-Probst D, Moch H, Simcock M, Ochsenbein A, Gillissen S, Schraml P, von Moos R. Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques. *Case Rep Oncol* 2012; 5(2):280-9.
259. Schraml P, von Teichman A, Mihic-Probst D, Simcock M, Ochsenbein A, Dummer R, Michielin O, Seifert B, Schlappi M, Moch H, von Moos R. Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. *Oncology reports* 2012; 28(2):654-8.
260. Schwanda-Burger S, Moch H, Muntwyler J, Salomon F. Diagnostic errors in the new millennium: a follow-up autopsy study. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc* 2012; 25(6):777-83.
261. Shakhova O, Zingg D, Schaefer SM, Hari L, Civenni G, Blunschli J, Claudinot S, Okoniewski M, Beermann F, Mihic-Probst D, Moch H, Wegner M, Dummer R, Barrandon Y, Cinelli P, Sommer L. Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma. *Nature cell biology* 2012; 14(8):882-90.
262. Varga Z, Moelans CB, Zuerrer-Hardi U, Ramach C, Behnke S, Kristiansen G, Moch H. Topoisomerase 2A gene amplification in breast cancer. Critical evaluation of different FISH probes. *Breast cancer research and treatment* 2012; 133(3):929-35.

263. Varga Z, Tubbs RR, Wang Z, Sun Y, Noske A, Kradolfer D, Bosshard G, Jochum W, Moch H, Ohlschlegel C. Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer. *Breast cancer research and treatment* 2012; 132(3):925-35.
264. von Moos R, Seifert B, Simcock M, Goldinger SM, Gillessen S, Ochsenbein A, Michielin O, Cathomas R, Schlappi M, Moch H, Schraml PH, Mjhić-Probst D, Mamot C, Schonewolf N, Dummer R. First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). *Ann Oncol* 2012; 23(2):531-6.
265. von Teichman A, Storz M, Dettwiler S, Moch H, Schraml P. Whole genome and transcriptome amplification: practicable tools for sustainable tissue biobanking? *Virchows Archiv : an international journal of pathology* 2012; 461(5):571-80.
266. Walter B, Hartmann A, Hofstadter F, Junker K, Moch H, Bertz S, Denzinger S, Otto W, Gajda M, Stoehr CG. Immunohistochemical marker panel differentiates between the three most common subtypes of renal cell carcinoma independent from histomorphologic criteria. *Virchows Archiv : an international journal of pathology* 2012; 460(3):343-52.
267. Wiedl T, Collaud S, Hillinger S, Arni S, Burgess C, Kroll W, Schraml P, Soltermann A, Moch H, Weder W. KRAS mutation is associated with elevated myeloblastin activity in human lung adenocarcinoma. *Cancer Genomics Proteomics* 2012; 9(1):51-4.
268. Wolf MJ, Hoos A, Bauer J, Boettcher S, Knust M, Weber A, Simonavicius N, Schneider C, Lang M, Sturzl M, Croner RS, Konrad A, Manz MG, Moch H, Aguzzi A, van Loo G, Pasparakis M, Prinz M, Borsig L, Heikenwalder M. Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway. *Cancer Cell* 2012; 22(1):91-105.
269. Wulf MA, Bode B, Zimmermann D, Rufibach K, Weder W, Moch H, Soltermann A, Tischler V. Silver-enhanced In Situ Hybridization for Determination of EGFR Copy Number Alterations in Non-Small Cell Lung Cancer. *The American journal of surgical pathology* 2012; 36(12):1801-8.
270. Zhou W, Otto EA, Cluckey A, Airik R, Hurd TW, Chaki M, Diaz K, Lach FP, Bennett GR, Gee HY, Ghosh AK, Natarajan S, Thongthip S, Veturi U, Allen SJ, Janssen S, Ramaswami G, Dixon J, Burkhalter F, Spoendlin M, Moch H, Mihatsch MJ, Verine J, Reade R, Soliman H, Godin M, Kiss D, Monga G, Mazzucco G, Amann K, Artunc F, Newland RC, Wiech T, Zschiedrich S, Huber TB, Friedl A, Slaats GG, Joles JA, Goldschmeding R, Washburn J, Giles RH, Levy S, Smogorzewska A, Hildebrandt F. FAN1 mutations cause karyomegalic interstitial nephritis, linking chronic kidney failure to defective DNA damage repair. *Nature genetics* 2012; 44(8):910-5.
271. Albers J, Rajski M, Schonenberger D, Harlander S, Schraml P, von Teichman A, Georgiev S, Wild PJ, Moch H, Krek W, Frew IJ. Combined mutation of Vhl and Trp53 causes renal cysts and tumours in mice. *EMBO Mol Med* 2013; 5(6):949-64.
272. Blyszczuk P, Berthonneche C, Behnke S, Glonkler M, Moch H, Pedrazzini T, Luscher TF, Eriksson U, Kania G. Nitric oxide synthase 2 is required for conversion of pro-fibrogenic inflammatory CD133(+) progenitors into F4/80(+) macrophages in experimental autoimmune myocarditis. *Cardiovasc Res* 2013; 97(2):219-29.
273. Boos LA, Dettmer M, Schmitt A, Rudolph T, Steinert H, Moch H, Sobrinho-Simoes M, Komminoth P, Perren A. Diagnostic and prognostic implications of the PAX8-

- PPARgamma translocation in thyroid carcinomas-a TMA-based study of 226 cases. *Histopathology* 2013; 63(2):234-41.
274. Braun M, Kirsten R, Rupp NJ, Moch H, Fend F, Wernert N, Kristiansen G, Perner S. Quantification of protein expression in cells and cellular subcompartments on immunohistochemical sections using a computer supported image analysis system. *Histol Histopathol* 2013; 28(5):605-10.
275. Broglie MA, Soltermann A, Rohrbach D, Haile SR, Pawlita M, Studer G, Huber GF, Moch H, Stoeckli SJ. Impact of p16, p53, smoking, and alcohol on survival in patients with oropharyngeal squamous cell carcinoma treated with primary intensity-modulated chemoradiation. *Head Neck* 2013; 35(12):1698-706.
276. Casagrande S, Ruf M, Rechsteiner M, Morra L, Brun-Schmid S, von Teichman A, Krek W, Schraml P, Moch H. The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma. *The Journal of pathology* 2013; 229(4):525-34.
277. Dannenmann SR, Hermanns T, Bransi A, Matter C, von Boehmer L, Stevanovic S, Schraml P, Moch H, Knuth A, van den Broek M. Spontaneous peripheral T-cell responses toward the tumor-associated antigen cyclin D1 in patients with clear cell renal cell carcinoma. *Cancer Immunol Res* 2013; 1(5):288-95.
278. Dannenmann SR, Thielicke J, Stockli M, Matter C, von Boehmer L, Cecconi V, Hermanns T, Hefermehl L, Schraml P, Moch H, Knuth A, van den Broek M. Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. *Oncoimmunology* 2013; 2(3):e23562.
279. Deisl C, Simonin A, Anderegg M, Albano G, Kovacs G, Ackermann D, Moch H, Dolci W, Thorens B, M AH, Fuster DG. Sodium/hydrogen exchanger NHA2 is critical for insulin secretion in beta-cells. *Proceedings of the National Academy of Sciences of the United States of America* 2013; 110(24):10004-9.
280. Dettmer M, Perren A, Moch H, Komminoth P, Nikiforov YE, Nikiforova MN. Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma. *Thyroid* 2013; 23(11):1383-9.
281. Dettmer M, Vogetseder A, Durso MB, Moch H, Komminoth P, Perren A, Nikiforov YE, Nikiforova MN. MicroRNA expression array identifies novel diagnostic markers for conventional and oncocytic follicular thyroid carcinomas. *J Clin Endocrinol Metab* 2013; 98(1):E1-7.
282. Eichelberg C, Chun FK, Bedke J, Heuer R, Adam M, Moch H, Terracciano L, Hinrichs K, Dahlem R, Fisch M, Schlomm T, Sauter G, Minner S. Epithelial cell adhesion molecule is an independent prognostic marker in clear cell renal carcinoma. *International journal of cancer Journal international du cancer* 2013; 132(12):2948-55.
283. Eichelberg C, Minner S, Isbarn H, Burandt E, Terracciano L, Moch H, Kell A, Heuer R, Chun FK, Sauter G, Fisch M, Tennstedt P. Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma. *World J Urol* 2013; 31(4):847-53.
284. Fellmann J, Weisert JU, Soltermann A, Morand G, Morra L, Moch H, Huber GF, Probst R. Helicobacter pylori detected in pharyngeal and laryngeal pathologies in patients with proven gastric colonization. *Head Neck* 2013.
285. Lenggenhager D, Maggio EM, Moch H, Rossle M. HBME-1 expression in hyalinizing trabecular tumours of the thyroid gland. *Histopathology* 2013; 62(7):1092-7.

286. Pawlowski R, Muhl SM, Sulser T, Krek W, Moch H, Schraml P. Loss of PBRM1 expression is associated with renal cell carcinoma progression. *International journal of cancer Journal international du cancer* 2013; 132(2):E11-7.
287. Perner S, Rupp NJ, Braun M, Rubin MA, Moch H, Dietel M, Wernert N, Jung K, Stephan C, Kristiansen G. Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course. *International journal of cancer Journal international du cancer* 2013; 132(4):807-12.
288. Pflueger D, Sboner A, Storz M, Roth J, Comperat E, Bruder E, Rubin MA, Schraml P, Moch H. Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing. *Neoplasia* 2013; 15(11):1231-40.
289. Rechsteiner M, von Teichman A, Ruschoff JH, Fankhauser N, Pestalozzi B, Schraml P, Weber A, Wild P, Zimmermann D, Moch H. KRAS, BRAF, and TP53 Deep Sequencing for Colorectal Carcinoma Patient Diagnostics. *J Mol Diagn* 2013; 15(3):299-311.
290. Rechsteiner M, Zimmermann AK, Wild PJ, Caduff R, von Teichman A, Fink D, Moch H, Noske A. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. *Exp Mol Pathol* 2013; 95(2):235-41.
291. Reiner CS, Roessle M, Thiesler T, Eberli D, Klotz E, Frauenfelder T, Sulser T, Moch H, Alkadhi H. Computed tomography perfusion imaging of renal cell carcinoma: systematic comparison with histopathological angiogenic and prognostic markers. *Invest Radiol* 2013; 48(4):183-91.
292. Rossle M, Sigg M, Ruschoff JH, Wild PJ, Moch H, Weber A, Rechsteiner MP. Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma. *Virchows Archiv : an international journal of pathology* 2013; 463(5):623-31.
293. Rossle M, Weber CS, Zullig L, Graf N, Jochum W, Stockli SJ, Moch H, Huber GF. EGFR expression and copy number changes in low T-stage oral squamous cell carcinomas. *Histopathology* 2013; 63(2):271-8.
294. Roth P, Silginer M, Goodman SL, Hasenbach K, Thies S, Maurer G, Schraml P, Tabatabai G, Moch H, Tritschler I, Weller M. Integrin control of the transforming growth factor-beta pathway in glioblastoma. *Brain* 2013; 136(Pt 2):564-76.
295. Sharma A, Bode B, Studer G, Moch H, Okoniewski M, Knuth A, von Boehmer L, van den Broek M. Radiotherapy of human sarcoma promotes an intratumoral immune effector signature. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2013; 19(17):4843-53.
296. Teleki I, Krenacs T, Szasz MA, Kulka J, Wichmann B, Leo C, Papassotiropoulos B, Riemenschnitter C, Moch H, Varga Z. The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancer. *BMC Cancer* 2013; 13:50.
297. Tordella L, Koch S, Salter V, Pagotto A, Doondeea JB, Feller SM, Ratnayaka I, Zhong S, Goldin RD, Lozano G, McKeon FD, Tavassoli M, Fritzsche F, Huber GF, Rossle M, Moch H, Lu X. ASPP2 suppresses squamous cell carcinoma via RelA/p65-mediated repression of p63. *Proceedings of the National Academy of Sciences of the United States of America* 2013; 110(44):17969-74.
298. Varga Z, Noske A, Ramach C, Padberg B, Moch H. Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization

- and immunohistochemistry in a single institution over 12 years: a quality control study. *BMC Cancer* 2013; 13:615.
299. Varga Z, Sinn P, Fritzsche F, von Hochstetter A, Noske A, Schraml P, Tausch C, Trojan A, Moch H. Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer. *PLoS ONE* 2013; 8(3):e58483.
300. Vogetseder A, Thies S, Ingold B, Roth P, Weller M, Schraml P, Goodman SL, Moch H. α -Integrin isoform expression in primary human tumors and brain metastases. *International journal of cancer Journal international du cancer* 2013; 133(10):2362-71.
301. von Boehmer L, Mattle M, Bode P, Landshammer A, Schafer C, Nuber N, Ritter G, Old L, Moch H, Schafer N, Jager E, Knuth A, van den Broek M. NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma. *Cancer immunity* 2013; 13:12.
302. Zimmermann AK, Imig J, Klar A, Renner C, Korol D, Fink D, Stadlmann S, Singer G, Knuth A, Moch H, Caduff R. Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas. *Virchows Archiv : an international journal of pathology* 2013; 462(5):565-74.
303. Zullig L, Roessle M, Weber C, Graf N, Haerle SK, Jochum W, Stoeckli SJ, Moch H, Huber GF. High sex determining region Y-box 2 expression is a negative predictor of occult lymph node metastasis in early squamous cell carcinomas of the oral cavity. *European journal of cancer* 2013; 49(8):1915-22.
304. Bitanihirwe BK, Meerang M, Friess M, Soltermann A, Frischknecht L, Thies S, Felley-Bosco E, Tsao MS, Allo G, de Perrot M, Seifert B, Moch H, Stahel R, Weder W, Opitz I. PI3K/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy. *J Thorac Oncol* 2014; 9(2):239-47.
305. Blattner M, Lee DJ, O'Reilly C, Park K, MacDonald TY, Khani F, Turner KR, Chiu YL, Wild PJ, Dolgalev I, Heguy A, Sboner A, Ramazangolu S, Hieronymus H, Sawyers C, Tewari AK, Moch H, Yoon GS, Known YC, Andren O, Fall K, Demichelis F, Mosquera JM, Robinson BD, Barbieri CE, Rubin MA. SPOP mutations in prostate cancer across demographically diverse patient cohorts. *Neoplasia* 2014; 16(1):14-20.
306. Bode PK, Thielken A, Brandt S, Barghorn A, Lohe B, Knuth A, Moch H. Cancer testis antigen expression in testicular germ cell tumorigenesis. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc* 2014; 27(6):899-905.
307. Dettmer MS, Perren A, Moch H, Komminoth P, Nikiforov YE, Nikiforova MN. MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights. *J Mol Endocrinol* 2014; 52(2):181-9.
308. Fellmann J, Weisert JU, Soltermann A, Morand G, Morra L, Moch H, Huber GF, Probst R. Helicobacter pylori detected in pharyngeal and laryngeal pathologies in patients with proven gastric colonization. *Head Neck* 2014; 36(11):1562-6.
309. Hell MP, Duda M, Weber TC, Moch H, Krek W. Tumor suppressor VHL functions in the control of mitotic fidelity. *Cancer research* 2014; 74(9):2422-31.
310. Ikenberg K, Valtcheva N, Brandt S, Zhong Q, Wong CE, Noske A, Rechsteiner M, Rueschoff JH, Caduff R, Dellas A, Obermann E, Fink D, Fuchs T, Krek W, Moch H, Frew IJ, Wild PJ. KPNA2 is overexpressed in human and mouse endometrial cancers and promotes cellular proliferation. *The Journal of pathology* 2014; 234(2):239-52.

311. Koppensteiner R, Samartzis EP, Noske A, von Teichman A, Dedes I, Gwerder M, Imesch P, Ikenberg K, Moch H, Fink D, Stucki M, Dedes KJ. Effect of MRE11 Loss on PARP-Inhibitor Sensitivity in Endometrial Cancer In Vitro. *PLoS ONE* 2014; 9(6):e100041.
312. Lenggenhager D, Curioni-Fontecedro A, Storz M, Shakhova O, Sommer L, Widmer DS, Seifert B, Moch H, Dummer R, Mihic-Probst D. An Aggressive Hypoxia Related Subpopulation of Melanoma Cells is TRP-2 Negative. *Transl Oncol* 2014; 7(2):206-12.
313. Meller S, Bicker A, Montani M, Ikenberg K, Rostamzadeh B, Sailer V, Wild P, Dietrich D, Uhl B, Sulser T, Moch H, Gorr TA, Stephan C, Jung K, Hankeln T, Kristiansen G. Myoglobin expression in prostate cancer is correlated to androgen receptor expression and markers of tumor hypoxia. *Virchows Archiv : an international journal of pathology* 2014; 465(4):419-27.
314. Noske A, Henricksen LA, LaFleur B, Zimmermann A, Tubbs A, Singh S, Storz M, Fink D, Moch H. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes. *Exp Mol Pathol* 2014; 98(1):47-54.
315. Poyet C, Jentsch B, Hermanns T, Schweckendiek D, Seifert HH, Schmidpeter M, Sulser T, Moch H, Wild PJ, Kristiansen G. Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer. *BMC Clin Pathol* 2014; 14(1):10.
316. Rechsteiner M, Muller R, Reineke T, Goede J, Bohnert A, Zhong Q, Manz MG, Moch H, Wild PJ, Zimmermann DR, Tinguely M. Modelling of a genetically diverse evolution of Systemic Mastocytosis with Chronic Myelomonocytic Leukemia (SM-CMML) by Next Generation Sequencing. *Exp Hematol Oncol* 2014; 3:18.
317. Rechsteiner MP, Floros X, Boehm BO, Marselli L, Marchetti P, Stoffel M, Moch H, Spinaz GA. Automated Assessment of beta-Cell Area and Density per Islet and Patient Using TMEM27 and BACE2 Immunofluorescence Staining in Human Pancreatic beta-Cells. *PLoS ONE* 2014; 9(6):e98932.
318. Theurillat JP, Udeshi ND, Errington WJ, Svinkina T, Baca SC, Pop M, Wild PJ, Blattner M, Groner AC, Rubin MA, Moch H, Prive GG, Carr SA, Garraway LA. Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. *Science* 2014; 346(6205):85-9.
319. Varga Z, Tubbs RR, Moch H. Concomitant Detection of HER2 Protein and Gene Alterations by Immunohistochemistry (IHC) and Silver Enhanced In Situ Hybridization (SISH) Identifies HER2 Positive Breast Cancer with and without Gene Amplification. *PLoS ONE* 2014; 9(8):e105961.
320. von Laffert M, Warth A, Penzel R, Schirmacher P, Kerr KM, Elmberger G, Schildhaus HU, Buttner R, Lopez-Rios F, Reu S, Kirchner T, Pauwels P, Specht K, Drecoll E, Hofler H, Aust D, Baretton G, Bubendorf L, Stallmann S, Fisseler-Eckhoff A, Soltermann A, Tischler V, Moch H, Penault-Llorca F, Hager H, Schaper F, Lenze D, Hummel M, Dietel M. Multicenter Immunohistochemical ALK-Testing of Non-Small-Cell Lung Cancer Shows High Concordance after Harmonization of Techniques and Interpretation Criteria. *J Thorac Oncol* 2014; 9(11):1685-92.
321. Walter KM, Schonenberger MJ, Trotschmuller M, Horn M, Elsasser HP, Moser AB, Lucas MS, Schwarz T, Gerber PA, Faust PL, Moch H, Kofeler HC, Krek W, Kovacs WJ. Hif-2alpha promotes degradation of Mammalian peroxisomes by selective autophagy. *Cell Metab* 2014; 20(5):882-97.

322. Wang Y, Bu F, Royer C, Serres S, Larkin JR, Soto MS, Sibson NR, Salter V, Fritzsche F, Turnquist C, Koch S, Zak J, Zhong S, Wu G, Liang A, Olofsen PA, Moch H, Hancock DC, Downward J, Goldin RD, Zhao J, Tong X, Guo Y, Lu X. ASPP2 controls epithelial plasticity and inhibits metastasis through beta-catenin-dependent regulation of ZEB1. *Nature cell biology* 2014; 16(11):1092-104.
323. Wolf MJ, Adili A, Piotrowitz K, Abdullah Z, Boege Y, Stemmer K, Ringelhan M, Simonavicius N, Egger M, Wohlleber D, Lorentzen A, Einer C, Schulz S, Clavel T, Protzer U, Thiele C, Zischka H, Moch H, Tschop M, Tumanov AV, Haller D, Unger K, Karin M, Kopf M, Knolle P, Weber A, Heikenwalder M. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. *Cancer Cell* 2014; 26(4):549-64.
324. Wyler L, Napoli CU, Ingold B, Sulser T, Heikenwalder M, Schraml P, Moch H. Brain metastasis in renal cancer patients: metastatic pattern, tumour-associated macrophages and chemokine/chemoreceptor expression. *British journal of cancer* 2014; 110(3):686-94.
325. Bieri U, Moch H, Dehler S, Korol D, Rohrmann S. Changes in autopsy rates among cancer patients and their impact on cancer statistics from a public health point of view: a longitudinal study from 1980 to 2010 with data from Cancer Registry Zurich. *Virchows Archiv : an international journal of pathology* 2015; 466(6):637-43.
326. Curioni-Fontecedro A, Martin V, Vogetseder A, Knuth A, Moch H, Soldini D, Tinguely M. Chromosomal aberrations of cancer-testis antigens in myeloma patients. *Hematol Oncol* 2015; 33(3):159-63.
327. Curioni-Fontecedro A, Pitocco R, Schoenewolf NL, Holzmann D, Soldini D, Dummer R, Calvieri S, Moch H, Mihic-Probst D, Fitsche A. Intratumoral Heterogeneity of MAGE-C1/CT7 and MAGE-C2/CT10 Expression in Mucosal Melanoma. *Biomed Res Int* 2015; 2015:432479.
328. Deml KF, Schildhaus HU, Comperat E, von Teichman A, Storz M, Schraml P, Bonventre JV, Fend F, Fleige B, Nerlich A, Gabbert HE, GaBler N, Grobholz R, Hailemariam S, Hinze R, Knuchel R, Lhermitte B, Nesi G, Rudiger T, Sauter G, Moch H. Clear Cell Papillary Renal Cell Carcinoma and Renal Angiomyoadenomatous Tumor: Two Variants of a Morphologic, Immunohistochemical, and Genetic Distinct Entity of Renal Cell Carcinoma. *The American journal of surgical pathology* 2015; 39(7):889-901.
329. Dettmer M, Schmitt A, Steinert H, Capper D, Moch H, Komminoth P, Perren A. Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT. *Endocrine-related cancer* 2015; 22(3):419-29.
330. Eppler E, Janas E, Link K, Weidmann L, Bischofberger H, Wenger M, Tinguely M, Schraml P, Moch H, Fellbaum C. Insulin-like growth factor I is expressed in classical and nodular lymphocyte-predominant Hodgkin's lymphoma tumour and microenvironmental cells. *Cell Tissue Res* 2015; 359(3):841-51.
331. Fankhauser CD, Curioni-Fontecedro A, Allmann V, Beyer J, Tischler V, Sulser T, Moch H, Bode PK. Frequent PD-L1 expression in testicular germ cell tumors. *British journal of cancer* 2015; 113(3):411-3.
332. Fankhauser CD, Sulser T, Zhong Q, Barghorn A, Moch H, Bode PK. CD10 expression in 325 testicular germ cell tumours. *Journal of clinical pathology* 2015; 68(5):400-3.
333. Feilchenfeldt J, Varga Z, Siano M, Grabsch HI, Held U, Schuknecht B, Trip A, Hamaguchi T, Gut P, Balague O, Khanfir K, Diebold J, Jochum W, Shoji H, Kushima

- R, Wagner D, Shimada Y, Cats A, Knuth A, Moch H, Aebi S, Hofer S. Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2). *British journal of cancer* 2015; 113(5):716-21.
334. Fluri F, Grunstein D, Cam E, Ungethuen U, Hatz F, Schafer J, Samnick S, Israel I, Kleinschnitz C, Orts-Gil G, Moch H, Zeis T, Schaeren-Wiemers N, Seeberger P. Fullerenols and glucosamine fullerenes reduce infarct volume and cerebral inflammation after ischemic stroke in normotensive and hypertensive rats. *Exp Neurol* 2015; 265:142-51.
335. Friemel J, Rechsteiner M, Frick L, Bohm F, Struckmann K, Egger M, Moch H, Heikenwalder M, Weber A. Intratumor heterogeneity in hepatocellular carcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2015; 21(8):1951-61.
336. Frischknecht L, Meerang M, Soltermann A, Stahel R, Moch H, Seifert B, Weder W, Opitz I. Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery. *J Thorac Cardiovasc Surg* 2015; 149(6):1539-47 e1.
337. Hofmann A, Thiesler T, Gerrits B, Behnke S, Sobotzki N, Omasits U, Bausch-Fluck D, Bock T, Aebersold R, Moch H, Tinguely M, Wollscheid B. Surfaceome of classical Hodgkin and non-Hodgkin lymphoma. *Proteomics Clin Appl* 2015; 9(7-8):661-70.
338. Huber F, Montani M, Sulser T, Jaggi R, Wild P, Moch H, Gevensleben H, Schmid M, Wyder S, Kristiansen G. Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer -what has gone wrong? A blueprint for the way forward in biomarker studies. *British journal of cancer* 2015; 112(1):140-8.
339. Mangana J, Cheng PF, Schindler K, Weide B, Held U, Frauchiger AL, Romano E, Kahler KC, Rozati S, Rechsteiner M, Moch H, Michielin O, Garbe C, Hauschild A, Hoeller C, Dummer R, Goldinger SM. Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival? *PLoS ONE* 2015; 10(10):e0139438.
340. Mosquera JM, Varma S, Pauli C, MacDonald TY, Yashinskij JJ, Varga Z, Sboner A, Moch H, Rubin MA, Shin SJ. MAGI3-AKT3 fusion in breast cancer amended. *Nature* 2015; 520(7547):E11-2.
341. Noske A, Henricksen LA, LaFleur B, Zimmermann AK, Tubbs A, Singh S, Storz M, Fink D, Moch H. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes. *Exp Mol Pathol* 2015; 98(1):47-54.
342. Pflueger D, Mittmann C, Dehler S, Rubin MA, Moch H, Schraml P. Functional characterization of BC039389-GATM and KLK4-KRSP1 chimeric read-through transcripts which are up-regulated in renal cell cancer. *BMC Genomics* 2015; 16:247.
343. Poyet C, Buser L, Roudnicky F, Detmar M, Hermanns T, Mannhard D, Hohn A, Ruschoff J, Zhong Q, Sulser T, Moch H, Wild PJ. Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer. *Journal of clinical pathology* 2015; 68(10):819-24.
344. Ruf M, Mittmann C, Nowicka AM, Hartmann A, Hermanns T, Poyet C, van den Broek M, Sulser T, Moch H, Schraml P. pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of

- soluble CD27 in clear cell renal cell carcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2015; 21(4):889-98.
345. Shakhova O, Cheng P, Mishra PJ, Zingg D, Schaefer SM, Debbache J, Hausel J, Matter C, Guo T, Davis S, Meltzer P, Mihic-Probst D, Moch H, Wegner M, Merlino G, Levesque MP, Dummer R, Santoro R, Cinelli P, Sommer L. Antagonistic cross-regulation between Sox9 and Sox10 controls an anti-tumorigenic program in melanoma. *PLoS Genet* 2015; 11(1):e1004877.
 346. Winklhofer S, Peter S, Tischler V, Morsbach F, von Werdt M, Berens S, Modregger P, Buser L, Moch H, Stampanoni M, Thali M, Alkadhi H, Stolzmann P. Diagnostic Accuracy of Quantitative and Qualitative Phase-Contrast Imaging for the Ex Vivo Characterization of Human Coronary Atherosclerotic Plaques. *Radiology* 2015:141614.
 347. Beleut M, Soeldner R, Egorov M, Guenther R, Dehler S, Morys-Wortmann C, Moch H, Henco K, Schraml P. Discretization of Gene Expression Data Unmasks Molecular Subgroups Recurring in Different Human Cancer Types. *PLoS ONE* 2016; 11(8):e0161514.
 348. Fankhauser CD, Bode PK, Hermanns T, Sander S, Beyer J, Sulser T, Altevogt P, Moch H, Tischler V. L1-CAM is commonly expressed in testicular germ cell tumours. *Journal of clinical pathology* 2016; 69(5):460-2.
 349. Frauchiger AL, Mangana J, Rechsteiner M, Moch H, Seifert B, Braun RP, Dummer R, Goldinger SM. Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation status. *Br J Dermatol* 2016; 174(4):823-30.
 350. Gramatzki D, Frei K, Cathomas G, Moch H, Weller M, Mertz KD. Interleukin-33 in human gliomas: Expression and prognostic significance. *Oncol Lett* 2016; 12(1):445-52.
 351. Gugger A, Barnhill RL, Seifert B, Dehler S, Moch H, Lugassy C, Marques-Maggio E, Rushing EJ, Mihic-Probst D. Cutaneous Melanoma with Brain Metastasis: Report of 193 Patients with New Observations. *PLoS ONE* 2016; 11(5):e0156115.
 352. Lukamowicz-Rajska M, Mittmann C, Prummer M, Zhong Q, Bedke J, Hennenlotter J, Stenzl A, Mischo A, Bihl S, Schmidinger M, Vogl U, Blume I, Karlo C, Schraml P, Moch H. MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients. *Oncotarget* 2016.
 353. Mertz KD, Mager LF, Wasmer MH, Thiesler T, Koelzer VH, Ruzzante G, Joller S, Murdoch JR, Brummendorf T, Genitsch V, Lugli A, Cathomas G, Moch H, Weber A, Zlobec I, Junt T, Krebs P. The IL-33/ST2 pathway contributes to intestinal tumorigenesis in humans and mice. *Oncoimmunology* 2016; 5(1):e1062966.
 354. Mortezaei A, Keller EX, Poyet C, Hermanns T, Saba K, Randazzo M, Fankhauser CD, Wild PJ, Moch H, Sulser T, Eberli D. Clinical impact of prostate biopsy undergrading in an academic and community setting. *World J Urol* 2016; 34(10):1481-90.
 355. Noske A, Brandt S, Valtcheva N, Wagner U, Zhong Q, Bellini E, Fink D, Obermann EC, Moch H, Wild PJ. Detection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancer. *Oncotarget* 2016.

356. Nowicka AM, Hauselmann I, Borsig L, Bolduan S, Schindler M, Schraml P, Heikenwalder M, Moch H. A novel pVHL-independent but NEMO-driven pathway in renal cancer promotes HIF stabilization. *Oncogene* 2016; 35(24):3125-38.
357. Razafinjatovo C, Bihl S, Mischo A, Vogl U, Schmidinger M, Moch H, Schraml P. Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance. *BMC Cancer* 2016; 16:638.
358. Rohr UP, Binder C, Dieterle T, Giusti F, Messina CG, Toerien E, Moch H, Schafer HH. The Value of In Vitro Diagnostic Testing in Medical Practice: A Status Report. *PLoS ONE* 2016; 11(3):e0149856.
359. Rossle M, Cathomas G, Bonapace L, Sachs M, Dehler S, Storz M, Huber G, Moch H, Junt T, Mertz KD. Interleukin-33 Expression Indicates a Favorable Prognosis in Malignant Salivary Gland Tumors. *Int J Surg Pathol* 2016; 24(5):394-400.
360. Ruf M, Moch H, Schraml P. PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma. *International journal of cancer* 2016; 139(2):396-403.
361. Rupp NJ, Schuffler PJ, Zhong Q, Falkner F, Rechsteiner M, Ruschoff JH, Fankhauser C, Drach M, Largo R, Tremp M, Poyet C, Sulser T, Kristiansen G, Moch H, Buhmann J, Muntener M, Wild PJ. Oxygen supply maps for hypoxic microenvironment visualization in prostate cancer. *J Pathol Inform* 2016; 7:3.
362. Sobottka B, Pestalozzi B, Fink D, Moch H, Varga Z. Similar lymphocytic infiltration pattern in primary breast cancer and their corresponding distant metastases. *Oncimmunology* 2016; 5(6):e1153208.
363. Stoehr CG, Stoehr R, Wenners A, Hartmann A, Bertz S, Spath V, Walter B, Junker K, Moch H, Hinze R, Denzinger S, Bond EE, Bond GL, Bluemke K, Weigelt K, Lieb V, Nolte E, Fornara P, Wullich B, Taubert H, Wach S. Homozygous G/G variant of SNP309 in the human MDM2 gene is associated with earlier tumor onset in Caucasian female renal cell carcinoma patients. *Oncogenesis* 2016; 5:e205.
364. Stoehr CG, Walter B, Denzinger S, Ghiorzo P, Sturm RA, Hinze R, Moch H, Junker K, Hartmann A, Stoehr R. The Microphthalmia-Associated Transcription Factor p.E318K Mutation Does Not Play a Major Role in Sporadic Renal Cell Tumors from Caucasian Patients. *Pathobiology* 2016; 83(4):165-9.
365. Velizheva NP, Rechsteiner MP, Wong CE, Zhong Q, Rossle M, Bode B, Moch H, Soltermann A, Wild PJ, Tischler V. Cytology smears as excellent starting material for next-generation sequencing-based molecular testing of patients with adenocarcinoma of the lung. *Cancer Cytopathol* 2016.
366. Weller M, Nabors LB, Gorlia T, Leske H, Rushing E, Bady P, Hicking C, Perry J, Hong YK, Roth P, Wick W, Goodman SL, Hegi ME, Picard M, Moch H, Straub J, Stupp R. Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. *Oncotarget* 2016; 7(12):15018-32.
367. Widmann R, Caduff R, Giudici L, Zhong Q, Vogetseder A, Arlettaz R, Frey B, Moch H, Bode PK. Value of postmortem studies in deceased neonatal and pediatric intensive care unit patients. *Virchows Archiv : an international journal of pathology* 2016.
368. Zhong Q, Ruschoff JH, Guo T, Gabrani M, Schuffler PJ, Rechsteiner M, Liu Y, Fuchs TJ, Rupp NJ, Fankhauser C, Buhmann JM, Perner S, Poyet C, Blattner M, Soldini D, Moch H, Rubin MA, Noske A, Ruschoff J, Haffner MC, Jochum W, Wild PJ. Image-

based computational quantification and visualization of genetic alterations and tumour heterogeneity. *Sci Rep* 2016; 6:24146.

369. Boege Y, Malehmir M, Healy ME, Bettermann K, Lorentzen A, Vucur M, Ahuja AK, Bohm F, Mertens JC, Shimizu Y, Frick L, Remouchamps C, Mutreja K, Kahne T, Sundaravinayagam D, Wolf MJ, Rehrauer H, Koppe C, Speicher T, Padrisa-Altes S, Maire R, Schattenberg JM, Jeong JS, Liu L, Zwirner S, Boger R, Huser N, Davis RJ, Mullhaupt B, Moch H, Schulze-Bergkamen H, Clavien PA, Werner S, Borsig L, Luther SA, Jost PJ, Weinlich R, Unger K, Behrens A, Hillert L, Dillon C, Di Virgilio M, Wallach D, Dejardin E, Zender L, Naumann M, Walczak H, Green DR, Lopes M, Lavrik I, Luedde T, Heikenwalder M, Weber A. A Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer Development. *Cancer Cell* 2017; 32(3):342-59 e10.
370. Bogowicz M, Riesterer O, Ikenberg K, Stieb S, Moch H, Studer G, Guckenberger M, Tanadini-Lang S. Computed Tomography Radiomics Predicts HPV Status and Local Tumor Control After Definitive Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. *Int J Radiat Oncol Biol Phys* 2017.
371. Brandt S, Samartzis EP, Zimmermann AK, Fink D, Moch H, Noske A, Dedes KJ. Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer. *BMC Cancer* 2017; 17(1):44.
372. Casanova R, Xia D, Rulle U, Nanni P, Grossmann J, Vrugt B, Wettstein R, Ballester R, Astolfo A, Weder W, Moch H, Stampanoni M, Beck AH, Soltermann A. Morphoproteomic Characterization of Lung Squamous Cell Carcinoma Fragmentation, a Histological Marker of Increased Tumor Invasiveness. *Cancer research* 2017; 77(10):2585-93.
373. Chevrier S, Levine JH, Zanutelli VRT, Silina K, Schulz D, Bacac M, Ries CH, Ailles L, Jewett MAS, Moch H, van den Broek M, Beisel C, Stadler MB, Gedye C, Reis B, Pe'er D, Bodenmiller B. An Immune Atlas of Clear Cell Renal Cell Carcinoma. *Cell* 2017; 169(4):736-49 e18.
374. Corro C, Hejhal T, Poyet C, Sulser T, Hermanns T, Winder T, Prager G, Wild PJ, Frew I, Moch H, Rechsteiner M. Detecting circulating tumor DNA in renal cancer: An open challenge. *Exp Mol Pathol* 2017; 102(2):255-61.
375. Gut A, Moch H, Choschzick M. SOX2 Gene Amplification and Overexpression is Linked to HPV-positive Vulvar Carcinomas. *International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists* 2017.
376. Harlander S, Schonenberger D, Toussaint NC, Prummer M, Catalano A, Brandt L, Moch H, Wild PJ, Frew IJ. Combined mutation in Vhl, Trp53 and Rb1 causes clear cell renal cell carcinoma in mice. *Nature medicine* 2017; 23(7):869-77.
377. Hofmann AL, Behr J, Singer J, Kuipers J, Beisel C, Schraml P, Moch H, Beerenwinkel N. Detailed simulation of cancer exome sequencing data reveals differences and common limitations of variant callers. *BMC Bioinformatics* 2017; 18(1):8.
378. Janouskova H, El Tekle G, Bellini E, Udeshi ND, Rinaldi A, Ulbricht A, Bernasocchi T, Civenni G, Losa M, Svinkina T, Bielski CM, Kryukov GV, Cascione L, Napoli S, Enchev RI, Mutch DG, Carney ME, Berchuck A, Winterhoff BJN, Broaddus RR, Schraml P, Moch H, Bertoni F, Catapano CV, Peter M, Carr SA, Garraway LA, Wild PJ, Theurillat JP. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. *Nature medicine* 2017; 23(9):1046-54.

379. Mortezaei A, Salemi S, Rupp NJ, Ruschoff JH, Hermanns T, Poyet C, Randazzo M, Simon HU, Moch H, Sulser T, Wild P, Eberli D. Negative LC3b immunoreactivity in cancer cells is an independent prognostic predictor of prostate cancer specific death. *Oncotarget* 2017; 8(19):31765-74.
380. Noske A, Brandt S, Valtcheva N, Wagner U, Zhong Q, Bellini E, Fink D, Obermann EC, Moch H, Wild PJ. Detection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancer. *Oncotarget* 2017; 8(9):14794-805.
381. Razafinjatovo CF, Stiehl D, Deininger E, Rechsteiner M, Moch H, Schraml P. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFalpha degradation in clear cell renal cell carcinoma. *Oncotarget* 2017; 8(6):10199-212.
382. Singer J, Ruscheweyh HJ, Hofmann AL, Thurnherr T, Singer F, Toussaint NC, Ng CKY, Piscuoglio S, Beisel C, Christofori G, Dummer R, Hall MN, Krek W, Levesque M, Manz MG, Moch H, Papassotiropoulos A, Stekhoven DJ, Wild P, Wust T, Rinn B, Beerenwinkel N. NGS-pipe: a flexible, easily extendable, and highly configurable framework for NGS analysis. *Bioinformatics* 2017.
383. Velizheva NP, Rechsteiner MP, Wong CE, Zhong Q, Rossle M, Bode B, Moch H, Soltermann A, Wild PJ, Tischler V. Cytology smears as excellent starting material for next-generation sequencing-based molecular testing of patients with adenocarcinoma of the lung. *Cancer* 2017; 125(1):30-40.
384. Vital D, Holzmann D, Huber GF, Soyka MB, Moch H, Zimmermann DR, Ikenberg K. p16INK4a : A surrogate marker of high-risk human papillomavirus infection in squamous cell carcinoma of the nasal vestibule. *Head Neck* 2017; 39(7):1392-8.
385. Vital D, Huber GF, Holzmann D, Moch H, Ikenberg K. The presence of aberrant p53 pattern is a negative prognostic predictor in squamous cell carcinoma of the nasal vestibule. *Eur Arch Otorhinolaryngol* 2017.
386. Wang H, Schaefer T, Konantz M, Braun M, Varga Z, Paczulla AM, Reich S, Jacob F, Perner S, Moch H, Fehm TN, Kanz L, Schulze-Osthoff K, Lengerke C. Prominent Oncogenic Roles of EVI1 in Breast Carcinoma. *Cancer research* 2017; 77(8):2148-60.
387. Wettstein MS, Saba K, Umbehre MH, Murtola TJ, Fankhauser CD, Adank JP, Hofmann M, Sulser T, Hermanns T, Moch H, Wild P, Poyet C. Prognostic Role of Preoperative Serum Lipid Levels in Patients Undergoing Radical Prostatectomy for Clinically Localized Prostate Cancer. *Prostate* 2017; 77(5):549-56.
388. Widmann R, Caduff R, Giudici L, Zhong Q, Vogetseder A, Arlettaz R, Frey B, Moch H, Bode PK. Value of postmortem studies in deceased neonatal and pediatric intensive care unit patients. *Virchows Archiv : an international journal of pathology* 2017; 470(2):217-23.
389. Williamson SR, Gadde R, Trpkov K, Hirsch MS, Srigley JR, Reuter VE, Cheng L, Kunju LP, Barod R, Rogers CG, Delahunt B, Hes O, Eble JN, Zhou M, McKenney JK, Martignoni G, Fleming S, Grignon DJ, Moch H, Gupta NS. Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists. *Human pathology* 2017; 63:149-56.
390. Zhong Q, Guo T, Rechsteiner M, Ruschoff JH, Rupp N, Fankhauser C, Saba K, Mortezaei A, Poyet C, Hermanns T, Zhu Y, Moch H, Aebbersold R, Wild PJ. A curated collection of tissue microarray images and clinical outcome data of prostate cancer patients. *Sci Data* 2017; 4:170014.

Peer Reviewed Case Reports / Reviews / Letters :

1-117

1. Martin H, Abboud A, Rudolph B, Moch H, Gerl H. [Sellar germinoma with lung metastases]. *Zentralbl Pathol* 1991; 137(2):157-63.
2. Moch H, Kiener S, Dalquen P, Gudat F. [Pseudomesotheliomatous adenocarcinoma of the lung. Immunohistochemical study with special reference to detection of blood group isoantigens and Ber-EP4 antigen]. *Pathologe* 1993; 14(1):11-5.
3. Moch H, Sauter G, Gudat F, Waldman F, Mihatsch MJ. [Ki-67 fraction, p53 alteration and numerical chromosome aberrations (chromosomes 7 and 17) in formalin fixed bladder tumors]. *Verh Dtsch Ges Pathol* 1993; 77:226-30.
4. Sauter G, Moch H, Gudat F, Mihatsch MJ, Haley J, Meecker T, Waldman F. [Demonstration of gene amplification in urinary bladder cancer by fluorescent in situ hybridization (FISH)]. *Verh Dtsch Ges Pathol* 1993; 77:247-51.
5. Biermann CW, Moch H, Gasser TC, de Riese W, Rutishauser G. [Primary detection of malignant mesothelioma of the tunica vaginalis testis using the BMA-120 monoclonal antibody]. *Helv Chir Acta* 1994; 60(6):1127-9.
6. Buchholz NP, Moch H, Feichter GE, Schmid HP, Mihatsch MJ. Clinical and pathological features of highly malignant prostatic carcinomas with metastases to the penis. *Urol Int* 1994; 53(3):135-8.
7. Buchholz NP, Moch H, Mihatsch MJ. Late urinary bladder metastases after radical resection of prostatic carcinoma. *Urol Int* 1994; 53(1):50-2.
8. Habicht JM, Lori A, Stulz P, Gradel E, Perruchoud A, Moch H. Primary non-Hodgkin's lymphoma of the lung. Will videothoroscopic biopsy change decision-making with regard to resection of this disease? *Thorac Cardiovasc Surg* 1994; 42(2):112-5.
9. John H, Zimmerli W, Moch H. [Polyarthritis, malabsorption and abdominal tumor]. *Schweiz Rundsch Med Prax* 1994; 83(33):901-4.
10. Moch H, Ohnacker H, Epper R, Gudat F, Mihatsch MJ. A new case of malignant mesothelioma of the tunica vaginalis testis. Immunohistochemistry in comparison with an adenomatoid tumor of the testis. *Pathol Res Pract* 1994; 190(4):400-4; discussion 4-8.
11. Moch H, Spondlin M, Schmassmann A, Mihatsch MJ. [Systemic karyomegaly with chronic interstitial nephritis. Discussion of the disease picture based on an autopsy case]. *Pathologe* 1994; 15(1):44-8.
12. Buchholz NP, Moch H, Gasser TC, Linke RP, Thiel GT, Mihatsch MJ. Ureteral amyloid deposits of beta 2-microglobulin origin in both kidney recipients of 1 donor. *J Urol* 1995; 153(2):399-401.
13. Gasser TC, Sauter G, Moch H, Mihatsch MJ, Waldman FM. Chromosom-17-Heterogenität, p53-Alteration und Tumorwachstumsfraktion (Ki-67 LI) in Harnblasentumoren. *Akt Urol* 1995; 26:67-70.

14. Spöndlin M, Moch H, Brunner F, Brunner W, Burger HR, Kiss D, Wegmann W, Dalquen P, Oberholzer M, Thiel G, et al. Karyomegalic interstitial nephritis: further support for a distinct entity and evidence for a genetic defect. *Am J Kidney Dis* 1995; 25(2):242-52.
15. Raz HR, Moch H, Wagner P. [Acute kidney insufficiency in an alcoholic patient with liver cirrhosis]. *Schweiz Med Wochenschr* 1996; 126(30):1306-13.
16. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, Moch H, Reuter VE, Ritz E, Roos G, Schmidt D, Srigley JR, Storkel S, van den Berg E, Zbar B. The Heidelberg classification of renal cell tumours. *J Pathol* 1997; 183(2):131-3.
17. Sauter G, Moch H, Wagner U, Bubendorf L, Gasser TC, Mihatsch MJ. [Genomic changes in urinary bladder cancer]. *Verh Dtsch Ges Pathol* 1997; 81:287-96.
18. Moch H, Braun OM, Terracciano L, Mihatsch MJ. [Epithelioid angiomyolipoma of the kidney--a new tumor entity. Case report on a tumor with many multinucleated giant cells]. *Pathologe* 1998; 19(6):436-41.
19. Sauter G, Bubendorf L, Moch H, Gasser TC, Mihatsch MJ. [Cytogenetic changes in prostatic carcinoma]. *Pathologe* 1998; 19(1):63-8.
20. Sauter G, Moch H, Mihatsch MJ, Gasser TC. Molecular cytogenetics of bladder cancer progression. *Eur Urol* 1998; 33 Suppl 4:9-10.
21. Suess K, Moch H, Epper R, Koller A, Durmüller U, Mihatsch MJ. [Heterogeneity of seminal vesicle amyloid. Immunohistochemical detection of lactoferrin and amyloid of the prealbumin-transferrin type]. *Pathologe* 1998; 19(2):115-9.
22. Moch H, Wegmann W, Mihatsch MJ. [Autopsy and modern medicine]. *Schweiz Rundsch Med Prax* 1999; 88(19):861-7.
23. Ulrich S, Wagner U, Moch H, Richter J, Wegmann W. [Renal oncocytomatosis]. *Pathologe* 1999; 20(3):189-94.
24. Moch H, Schraml P, Bubendorf L, Mirlacher M, Kononen J, Gasser T, Mihatsch MJ, Kallioniemi OP, Sauter G. [Identification of prognostic parameters for renal cell carcinoma by cDNA arrays and cell chips]. *Verh Dtsch Ges Pathol* 1999; 83:225-32.
25. Schraml P, Zhaou M, Richter J, Bruning T, Pommer M, Sauter G, Mihatsch MJ, Moch H. [Analysis of kidney tumors in trichloroethylene exposed workers by comparative genomic hybridization and DNA sequence analysis]. *Verh Dtsch Ges Pathol* 1999; 83:218-24.
26. Colombo E, Krause M, Moch H. [Anemia and thrombocytopenia of uncertain etiology]. *Schweiz Med Wochenschr* 2000; 130(51-52):2009-16.
27. Bubendorf L, Nocito A, Moch H, Sauter G. Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. *J Pathol* 2001; 195(1):72-9.
28. Casella R, Moch H, Rochlitz C, Meier V, Seifert B, Mihatsch MJ, Gasser TC. Metastatic primitive neuroectodermal tumor of the kidney in adults. *Eur Urol* 2001; 39(5):613-7.
29. Moch H. BK-virus nephropathy in renal allografts: a new diagnostic challenge in transplant pathology (news in brief). *Adv Anat Pathol* 2001; 8(4):246-8.

30. Moch H, Kononen T, Kallioniemi OP, Sauter G. Tissue microarrays: what will they bring to molecular and anatomic pathology? *Adv Anat Pathol* 2001; 8(1):14-20.
31. Dellas A, Torhorst J, Mihatsch M, Moch H. Genomische Aberrationen beim invasiven Zervixkarzinom. *Geburtsh Frauenheilk* 2002; 62:458-64.
32. Moch H. [Renal tumors in adults: rare tumors and new tumor entities]. *Verh Dtsch Ges Pathol* 2002; 86:40-8.
33. Lugli A, Stoffe F, Terracciano L, Dirnhofer S, Mihatsch MJ, Moch H. [Differentiated papillary kidney tumors. Differentiation between metanephric adenoma and papillary adenoma]. *Pathologe* 2002; 23(4):303-7.
34. Moch H, Mihatsch MJ. Genetic progression of renal cell carcinoma. *Virchows Arch* 2002; 441(4):320-7.
35. Rueter F, Hirsch HH, Kunz F, Buser P, Habicht JM, Moch H, Fluckiger U, Zerkowski HR. Late *Aspergillus fumigatus* endomyocarditis with brain abscess as a lethal complication after heart transplantation. *J Heart Lung Transplant* 2002; 21(11):1242-5.
36. Guller U, Nitzsche E, Moch H, Zuber M. Is positron emission tomography an accurate non-invasive alternative to sentinel lymph node biopsy in breast cancer patients? *J Natl Cancer Inst* 2003; 95(14):1040-3.
37. Moch H, Wodzinski A, Guillou L, Nickeleit V. [Primary renal synovial sarcoma. A new entity in the morphological spectrum of spindle cell renal tumors]. *Pathologe* 2003; 24(6):466-72.
38. Singer G, Schraml P, Belgard C, Raggi A, Dirnhofer S, Went P, Mihatsch MJ, Moch H. KIT in ovarian carcinoma: disillusion about a potential therapeutic target. *J Natl Cancer Inst* 2003; 95(13):1009-10.
39. Weber A, Srigley J, Moch H. [Mucinous spindle cell carcinoma of the kidney. A molecular analysis]. *Pathologe* 2003; 24(6):453-9.
40. Bruder E, Moch H. [Pediatric renal cell carcinoma]. *Pathologe* 2004; 25(4):324-7.
41. Guth U, Wight E, Moch H, Holzgreve W. Detection of minute breast cancers: a therapeutic challenge with a potential danger of overtreatment. *Breast J* 2004; 10(4):373-4.
42. Moch H. Genomic alterations in renal tumours: what have we learned in the era of comparative genomic hybridisation? *Pathology* 2004; 36(1):51-7.
43. Moch H, Schurch LV, Sulser T, Terracciano L. [Mixed epithelial and stromal tumor of the kidney]. *Pathologe* 2004; 25(5):356-61.
44. Baker PM, Moch H, Oliva E. Unusual Morphologic Features of Endometrial Stromal Tumors: A Report of 2 Cases. *Am J Surg Pathol* 2005; 29(10):1394-8.
45. Struckmann K, Mertz K, Staller P, Krek W, Schraml P, Moch H. mRNA Expression Analysis of Metastatic Markers in Renal Cell Carcinoma. *Verh Dtsch Ges Pathol* 2005; 89:178-83.
46. Mertz K, Moch H. Abnormally multiplied transcription factor serves as an 'addiction' oncogene in malignant melanoma. *Adv Anat Pathol* 2005; 12(6):360.

47. Moch H. [The new classification of renal tumors--what is relevant for the practice?]. *Schweiz Rundsch Med Prax* 2005; 94(33):1261-5.
48. Mertz KD, Tchinda J, Kufer R, Moller P, Rubin MA, Moch H, Perner S. [Cytogenetic alterations in renal tumors Applications for comparative genomic hybridization and fluorescence in situ hybridization.]. *Urologe A* 2006; 45(3):316-22.
49. Perren A, Wiesli P, Schmid S, Montani M, Schmitt A, Schmid C, Moch H, Komminoth P. Pancreatic Endocrine Tumors are a Rare Manifestation of the Neurofibromatosis Type 1 Phenotype: Molecular Analysis of a Malignant Insulinoma in a NF-1 Patient. *Am J Surg Pathol* 2006; 30(8):1047-51.
50. Giger OT, Lacoste E, Honegger C, Padberg B, Moch H, Varga Z. Expression of the breast differentiation antigen NY-BR-1 in a phyllodes tumor of the vulva. *Virchows Arch* 2007; 450(4):471-4.
51. Theurillat JP, Moch H. Autophagy-an emerging tumor suppressor pathway. *Adv Anat Pathol* 2007; 14(3):232.
52. Stoerkel S, Kristiansen G, Moch H. The importance of pathology and genetics for the diagnosis and therapy of renal cell carcinoma. *European Urology* 2007; 6:603-10.
53. Corsenca A, Aebersold F, Moch H, Bird P, Weber M, Hofbauer G, Wuthrich RP, Serra AL. Combined nephrectomy and pre-emptive renal transplantation in a tuberous sclerosis patient with angiomyolipoma, renal carcinoma and life-threatening abdominal haemorrhages. *Nephrol Dial Transplant* 2007; 22(11):3330-3.
54. Varga Z, Rageth C, Saurenmann E, Honegger C, von Orelli S, Fehr M, Fink D, Seifert B, Moch H, Caduff R. [Loss of metastatic deposits in breast sentinel lymph nodes during intra-operative frozen section analysis]. *Verh Dtsch Ges Pathol* 2007; 91:221-4.
55. Luu VD, Fischer B, von Teichman A, Boysen G, Mertz K, Zimmermann P, Moch H, Schraml P. [Von-Hippel-Lindau gene mutation types. Association of gene expression signatures in clear cell renal cell carcinoma]. *Pathologe* 2008; 29 Suppl 2:303-7.
56. Moch H. [Molecular basis of targeted therapy in metastatic renal cancer]. *Pathologe* 2008; 29 Suppl 2:184-6.
57. Moch H. [Von-Hippel-Lindau (VHL) protein function by initiation and progression of renal cancer]. *Pathologe* 2008; 29 Suppl 2:149-52.
58. Tinguely M, Hofmann A, Bausch-Fluck D, Moch H, Wollscheid B. Immunophenotyping without antibodies : New perspectives for lymphoma characterization. *Pathologe* 2008.
59. Spahn DR, Moch H, Hofmann A, Isbister JP. Patient blood management: the pragmatic solution for the problems with blood transfusions. *Anesthesiology* 2008; 109(6):951-3.
60. Moch H, Artibani W, Delahunt B, Ficarra V, Knuechel R, Montorsi F, Patard JJ, Stief CG, Sulser T, Wild PJ. Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. *Eur Urol* 2009; 56(4):636-43.
61. Fritzsche FR, Kristiansen G, Frauenfelder T, Opitz I, Bode P, Moch H, Montani M. Large mixed germ cell tumor in a young patient presenting as an intrapulmonary mass. *Pathol Res Pract* 2009.

62. Eichelberg C, Junker K, Ljungberg B, Moch H. Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. *Eur Urol* 2009; 55(4):851-63.
63. Boysen G, Wollscheid B, Bausch-Fluck D, Schraml P, Moch H. [Identification of VHL-associated changes in clear cell renal carcinoma: the application of combined genome and expression analyses]. *Pathologe* 2009; 30 Suppl 2:188-92.
64. Soltermann A, Moch H. Klinisch relevante Biomarker des nicht kleinzelligen Lungenkarzinoms. *The Medical Journal* 2009; 4:26-9.
65. Moch H. [Cystic renal neoplasms. New entities and molecular findings]. *Pathologe* 2010; 31 Suppl 2:239-43.
66. Moch H. Cystic renal tumors: new entities and novel concepts. *Adv Anat Pathol* 2010; 17(3):209-14.
67. Algaba F, Akaza H, Lopez-Beltran A, Martignoni G, Moch H, Montironi R, Reuter V. Current pathology keys of renal cell carcinoma. *European Urology* 2011; 60(4):634-43.
68. Barrascout E, Beuselinck B, Ayllon J, Battig B, Moch H, Teghom C, Oudard S. Complete remission of pulmonary metastases of Bellini duct carcinoma with cisplatin, gemcitabine and bevacizumab. *Am J Case Rep* 2012; 13:1-2.
69. Moch H. [Renal cancer biomarkers : What is justified?]. *Der Pathologe* 2012.
70. Moch H, Blank PR, Dietel M, Elmberger G, Kerr KM, Palacios J, Penault-Llorca F, Rossi G, Szucs TD. Personalized cancer medicine and the future of pathology. *Virchows Archiv : an international journal of pathology* 2012; 460(1):3-8.
71. Thunnissen E, Bubendorf L, Dietel M, Elmberger G, Kerr K, Lopez-Rios F, Moch H, Olszewski W, Pauwels P, Penault-Llorca F, Rossi G. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. *Virchows Archiv : an international journal of pathology* 2012; 461(3):245-57.
72. Brandt S, Lohe B, Vogetseder A, Rudiger T, Moch H, Bode P. [Primitive neuroectodermal tumor of the testis. Molecular analysis and discussion of genesis]. *Der Pathologe* 2013; 34(1):70-3.
73. Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J, Egevad L, Algaba F, Moch H, Grignon DJ, Montironi R, Srigley JR. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. *The American journal of surgical pathology* 2013; 37(10):1490-504.
74. Kench JG, Delahunt B, Griffiths DF, Humphrey PA, McGowan T, Trpkov K, Varma M, Wheeler TM, Srigley JR. Dataset for reporting of prostate carcinoma in radical prostatectomy specimens: recommendations from the International Collaboration on Cancer Reporting. *Histopathology* 2013; 62(2):203-18.
75. Moch H. An overview of renal cell cancer: pathology and genetics. *Semin Cancer Biol* 2013; 23(1):3-9.
76. Sanjmyatav J, Hauke S, Gajda M, Hartmann A, Moch H, Meyer B, Pryalukhin A, Grimm MO, Junker K. Establishment of a multicolour fluorescence in situ hybridisation-based assay for subtyping of renal cell tumours. *European Urology* 2013; 64(4):689-91.

77. Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, Hes O, Moch H, Montironi R, Tickoo SK, Zhou M, Argani P. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. *The American journal of surgical pathology* 2013; 37(10):1469-89.
78. Tan PH, Cheng L, Rioux-Leclercq N, Merino MJ, Netto G, Reuter VE, Shen SS, Grignon DJ, Montironi R, Egevad L, Srigley JR, Delahunt B, Moch H. Renal tumors: diagnostic and prognostic biomarkers. *The American journal of surgical pathology* 2013; 37(10):1518-31.
79. Zeh N, Wild PJ, Bode PK, Kristiansen G, Moch H, Sulser T, Hermanns T. Retroperitoneal teratoma with somatic malignant transformation: a papillary renal cell carcinoma in a testicular germ cell tumour metastasis following platinum-based chemotherapy. *BMC Urol* 2013; 13:9.
80. Amin MB, Smith SC, Agaimy A, Argani P, Comperat EM, Delahunt B, Epstein JI, Eble JN, Grignon DJ, Hartmann A, Hes O, Hirsch MS, Jimenez RE, Kunju LP, Martignoni G, McKenney JK, Moch H, Montironi R, Paner GP, Rao P, Srigley JR, Tickoo SK, Reuter VE. Collecting duct carcinoma versus renal medullary carcinoma: an appeal for nosologic and biological clarity. *The American journal of surgical pathology* 2014; 38(7):871-4.
81. Berens S, Vogt P, Alkadhi H, Berger N, Moch H. [Thyroid-like follicular carcinoma of the kidney: a separate tumor entity?]. *Der Pathologe* 2014; 35(1):83-7.
82. Bode PK, Cathomas G, Vogt P, Moch H. [Clinical autopsy]. *Praxis (Bern 1994)* 2014; 103(2):65-9; quiz 70-1.
83. Bode PK, Moch H. [Testicular seminomas : The classical and the less classical ones]. *Der Pathologe* 2014; 35(3):224-31.
84. Moch H, Lukamowicz-Rajska M. miR-30c-2-3p and miR-30a-3p: new pieces of the jigsaw puzzle in HIF2alpha regulation. *Cancer Discov* 2014; 4(1):22-4.
85. Moch H, Srigley J, Delahunt B, Montironi R, Egevad L, Tan PH. Biomarkers in renal cancer. *Virchows Archiv : an international journal of pathology* 2014; 464(3):359-65.
86. Rioux-Leclercq N, Ferran A, Mahul A, Argani P, Billis A, Bonsib S, Cheng L, Chevillet J, Eble J, Egevad L, Epstein J, Grignon D, Hes O, Humphrey P, Magi-Galluzzi C, Martignoni G, McKenney J, Merino M, Moch H, Montironi R, Netto G, Reuter V, Samarasinghe H, Shen S, Srigley J, Tamboli P, Tan PH, Tickoo S, Trpkov K, Zhou M, Delahunt B, Comperat E. [Renal tumors: The International Society of Urologic Pathology (ISUP) 2012 consensus conference recommendations]. *Ann Pathol* 2014; 34(6):448-61.
87. Sanjmyatav J, Hartmann A, Moch H, Hauke S, Gajda M, Meyer B, Pryalukhin A, Grimm MO, Junker K. Reply to Jerome Verine, Christophe Leboeuf and Philippe Ratajczak's letter to the editor re: Jimsgene Sanjmyatav, Sven Hauke, Mieczyslaw Gajda, et al. Establishment of a multicolour fluorescence in situ hybridisation-based assay for subtyping of renal cell tumours. *Eur Urol* 2013;64:689-91. *European Urology* 2014; 65(5):e71-2.
88. Fisher KW, Montironi R, Lopez Beltran A, Moch H, Wang L, Scarpelli M, Williamson SR, Koch MO, Cheng L. Molecular foundations for personalized therapy in prostate cancer. *Curr Drug Targets* 2015; 16(2):103-14.
89. Frew IJ, Moch H. A clearer view of the molecular complexity of clear cell renal cell carcinoma. *Annu Rev Pathol* 2015; 10:263-89.

90. Lopez-Beltran A, Santoni M, Massari F, Ciccamese C, Tortora G, Cheng L, Moch H, Scarpelli M, Reymundo C, Montironi R. Bladder cancer: molecular determinants of personalized therapy. *Curr Drug Targets* 2015; 16(2):115-24.
91. Moch H. [Neuroendocrine tumors of the kidneys]. *Der Pathologe* 2015; 36(3):278-82.
92. Moch H, Montironi R, Lopez-Beltran A, Cheng L, Mischo A. Oncotargets in different renal cancer subtypes. *Curr Drug Targets* 2015; 16(2):125-35.
93. Montironi R, Santoni M, Lopez-Beltran A, Cheng L, Moch H, Scarpelli M. Morphologic and molecular backgrounds for personalized management of genitourinary cancers: an overview. *Curr Drug Targets* 2015; 16(2):96-102.
94. Rechsteiner M, Wild P, Kiessling MK, Bohnert A, Zhong Q, Stahel RA, Moch H, Curioni-Fontecedro A. A novel germline mutation of PDGFR-beta might be associated with clinical response of colorectal cancer to regorafenib. *Ann Oncol* 2015; 26(1):246-8.
95. Ruf M, Moch H, Schraml P. Interaction of tumor cells with infiltrating lymphocytes via CD70 and CD27 in clear cell renal cell carcinoma. *Oncimmunology* 2015; 4(12):e1049805.
96. Schodel J, Grampp S, Maher ER, Moch H, Ratcliffe PJ, Russo P, Mole DR. Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer. *European urology* 2016; 69(4):646-57.
97. Schneider D, Riegman PH, Cronin M, Negrouk A, Moch H, Balling R, Penault-Llorca F, Zatloukal K, Horgan D. Accelerating the Development and Validation of New Value-Based Diagnostics by Leveraging Biobanks. *Public Health Genomics* 2016; 19(3):160-9.
98. Rausch S, Scharpf M, Moch H, Stenzl A, Bedke J. [Leiomyomatous renal cell carcinoma : Controversy around a new entity]. *Der Urologe Ausg A* 2016; 55(3):376-80.
99. Montironi R, Santoni M, Sotte V, Cheng L, Lopez-Beltran A, Massari F, Matrana MR, Moch H, Berardi R, Scarpelli M. Emerging Immunotargets and Immunotherapies in Prostate Cancer. *Curr Drug Targets* 2016; 17(7):777-82.
100. Montironi R, Santoni M, Cheng L, Lopez-Beltran A, Massari F, Matrana MR, Moch H, Scarpelli M. An Overview of Emerging Immunotargets of Genitourinary Tumors. *Curr Drug Targets* 2016; 17(7):750-6.
101. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. *European urology* 2016; 70(1):93-105.
102. Moch H. [Kidney tumours]. *Der Pathologe* 2016; 37(2):125-6.
103. Moch H. [WHO classification 2016 and first S3 guidelines on renal cell cancer: What is important for the practice?]. *Der Pathologe* 2016; 37(2):127-33.
104. Moch H. [The WHO/ISUP grading system for renal carcinoma]. *Der Pathologe* 2016; 37(4):355-60.
105. Massari F, Ciccamese C, Vau N, Santoni M, Montironi R, Cheng L, Marques RC, Scarpelli M, Fonseca J, Matrana MR, Holger M, Cascinu S, Tortora G, Lopez-Beltran A. Emerging Immunotargets in Bladder Cancer. *Curr Drug Targets* 2016; 17(7):757-70.

106. Kucharczyk J, Matrana MR, Santoni M, Massari F, Scarpelli M, Cheng L, Lopez-Beltran A, Cascinu S, Montironi R, Moch H. Emerging Immunotargets in Metastatic Renal Cell Carcinoma. *Curr Drug Targets* 2016; 17(7):771-6.
107. Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. *European urology* 2016; 70(1):106-19.
108. Bruder E, Moch H. [The translocation carcinoma: A pediatric renal tumor also in adults]. *Der Pathologe* 2016; 37(2):159-65.
109. Bode PK, Moch H. [Nephroblastomas: Almost exclusively in clinical trials!]. *Der Pathologe* 2016; 37(2):166-71.
110. Valtcheva N, Lang FM, Noske A, Samartzis EP, Schmidt AM, Bellini E, Fink D, Moch H, Rechsteiner M, Dedes KJ, Wild PJ. Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report. *BMC Cancer* 2017; 17(1):66.
111. Rupp NJ, Mischo A, Moch H. *Ther Umsch* 2017; 74(4):171-9.
112. Rodewald AK, Bode P, Cathomas G, Moch H. [Clinical autopsies in Switzerland : A status report]. *Pathologe* 2017; 38(5):416-21.
113. Pauli C, Moch H, Rubin MA. [Establishment of a living biobank : Improved guidance of precision cancer care with in vitro and in vivo cancer models]. *Pathologe* 2017; 38(Suppl 2):160-8.
114. Blanca A, Cheng L, Montironi R, Moch H, Massari F, Fiorentino M, Raspollini MR, Scarpelli M, Lopez-Beltran A. Mirna Expression in Bladder Cancer and Their Potential Role in Clinical Practice. *Curr Drug Metab* 2017; 18(8):712-22.
115. Mann SA, Lopez-Beltran A, Massari F, Pili R, Fiorentino M, Koch MO, Kaimakliotis HZ, Wang L, Scarpelli M, Ciccamese C, Moch H, Montironi R, Cheng L. Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives. *Curr Drug Metab* 2017; 18(8):700-11.
116. Giunchi F, Ciccamese C, Montironi R, Scarpelli M, Lopez-Beltran A, Cheng L, Moch H, Massari F, Fiorentino M. Urinary Biomarkers for Prostate Cancer. *Curr Drug Metab* 2017; 18(8):723-6.
117. Ciccamese C, Montironi R, Fiorentino M, Martignoni G, Brunelli M, Iacovelli R, Lopez-Beltran A, Cheng L, Scarpelli M, Moch H, Tortora G, Massari F. Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment? *Curr Drug Metab* 2017; 18(8):692-9.

Books/Book Chapters/Articles/Editorials/Thesis/Work as Collaborator in Networks or Clinical Trials:

1-84

1. Moch H. Kryoresistenzsteigerung von humanem Knochenmark durch Antioxidantien., Humboldt-Universität, Berlin, 1986.
2. Moch H. Kryoresistenzsteigerung von Zellen mittels Penicillin/Fe(II) und D-alpha-Tocopherol. Berlin thesis, Humboldt-Universität, Berlin, 1988.

3. Deicke P, Moch H. Disseminierte Kryptokokkose bei einem Patienten mit chronischer lymphozytischer Leukose. *hautnah myk* 1991; 1:8-10.
4. Moch H, Deicke P. Formen invasiver Lungenaspergillosen. *hautnah myk* 1991; 1:26-8.
5. Moch H, Deicke P, Devaux S. Ungewöhnliche Candida-Sepsis mit Pleuraempyem durch *Candida albicans*. *hautnah myk* 1991; 1:10-1.
6. Mihatsch M, Ryffel B, Moch H, Gudat F. *Chronische Abstossung versus Ciclosporin-Toxizität: Gibt es eine sichere Diagnose ?*, Pabst Science Publishers 1992.
7. Mihatsch M, Ryffel B, Moch H, Feutren G, Thiel G. Wandel der Ciclosporin-Nephrotoxizität. *Nieren-und Hochdruckkrankheiten* 1993; 22:71-6.
8. Sauter G, Gudat F, Torhorst J, Moch H, Feichter G, Nüsing R, Dürmüller U, Mihatsch M, Ullrich V. *Immunohistochemical localization of thromboxane synthase in normal and neoplastic tissues by the monoclonal antibody Tü 300*, Kluwer Academic Publisher: Boston, 1993.
9. Sauter G, Gasser T, Moch H, Mihatsch M. Pathogenese und Diagnostik des Harnblasenkarzinoms. *Geriatric Praxis* 1996; 5:31-5.
10. Mihatsch M, Brunner F, Sauter G, Moch H, Stroem E, Kutzera S, Rohr H. Nierenpathologie. 1997.
11. Moch H, Urrejola C, Herrmann P, Torhorst J, Sauter G, Mihatsch M. *Nierentumoren bei Langzeit-Hämodialyse und in Schrumpfnieren*, Pabst Science Publishers: Lengerich, Berlin, Düsseldorf, Leipzig, Riga, Scottsdale AZ (USA), Wien, Zagreb, 1997.
12. Moch H, Flury U, Torhorst J, Mihatsch MJ. Basisinformationen zur makroskopischen Beschreibung der Operationspräparate und Gewebeentnahme für Histologie. Universität Basel, Basel, 1997.
13. Pabst T, Rochlitz C, Moch H, Herrmann R. Chemotherapie bei Aesthesioneuroblastomen. *Schw Krebsbulletin* 1997; 17(3):94-7.
14. Moch H, Schraml P, Mirlacher M, Bubendorf L, Kononen J, Gasser T, Mihatsch M. *Genomic Screening for prognostic marker in renal cell carcinomas by cDNA-array and tumor-array technologies*, Blackwell Science Ltd: Berlin, Wien, Oxford, Edinburgh, Boston, London, Melbourne, Paris, Tokio, 1998.
15. Moch H, Gasser T, Richter J, Jiang F, Bissig H, Sauter G, Mihatsch M. *Analyse der epithelialen Nierentumor-Typen mittels Fluoreszenz-in-situ-Hybridisierung (FISH) und Comparative Genomic Hybridization (CGH)*, Blackwell Science Ltd: Berlin, Wien, Oxford, Edinburgh, Boston, London, Melbourne, Paris, Tokio, 1998.
16. Moch H. Pathologisch-anatomische und molekulargenetische Charakterisierung epithelialer Nierentumoren. Universität Basel, Basel, 1998.
17. Sauter G, Moch H. Molekulare Pathologie: Genetische Veränderungen in Tumorzellen. *UniNova* 1998; 81:34-43.
18. Moch H, Mihatsch M. *Autopsie und Qualitätssicherung*, 7 edn, Vol. IV-2.2.10.1, Ecomed Verlagsgesellschaft: Landsberg, 1999.

19. Sauter G, Moch H, Kallioniemi O-P. Tissue microarrays for rapid evaluation of prognostic parameters. In: Hauptmann S, Dietel M, Sobrino-Simoes M (eds). *Surgical Pathology Update 2001*, ABW Wissenschaftsverlag GmbH: Berlin, 2001, pp 210-3.
20. Moch H, Sauter G. Comparative Genomic Hybridization for the identification of putative prognostic parameters. In: Hauptmann S, Dietel M, Sobrino-Simoes M (eds). *Surgical Pathology Update 2001*, ABW Wissenschaftsverlag GmbH: Berlin, 2001, pp 204-6.
21. Pommer W, Moch H, Jonas D, Kuczyk M. Tumore der Niere, speziell Nierenzellkarzinom (NZK). In: Classen M, Dierkesmann R, Heimpel H, *et al.* (eds). *Rationelle Diagnostik und Therapie in der Inneren Medizin. Leitlinien*, Urban & Fischer: München, Jena, 2002.
22. Grignon D, Eble J, Bonsib S, Moch H. Clear Cell Renal Cell Carcinoma. In: Eble J, Sauter G, Epstein J, Sesterhenn I (eds). *World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs*, IARC Press: Lyon, 2004, pp 23-5.
23. Moch H. Gewebechips helfen bei der Etablierung von Krebsmedikamenten. *Puls* 2004; 4:20-2.
24. Srigley J, Moch H. Carcinoma of the collecting ducts of Bellini. In: Eble J, Sauter G, Epstein J, Sesterhenn I (eds). *World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs*, IARC Press: Lyon, 2004, pp 33-4.
25. Eble J, Moch H. Papillary adenoma of the kidney. In: Eble J, Sauter G, Epstein J, Sesterhenn I (eds). *World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs*, IARC Press: Lyon, 2004, p 41.
26. Reuter V, Davis C, Moch H. Oncocytoma. In: Eble J, Sauter G, Epstein J, Sesterhenn I (eds). *World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs*, IARC Press: Lyon, 2004, pp 42-3.
27. Eble J, Grignon D, Moch H. Metanephric adenoma and metanephric adenofibroma. In: Eble J, Sauter G, Epstein J, Sesterhenn I (eds). *World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs*, IARC Press: Lyon, 2004, pp 44-5.
28. Moch H. Early and late genetic changes in clear cell renal carcinoma. *Urologe A* 2004; 43 Suppl 3:121.
29. Nizze H, Kerjaschki D, Moch H. Niere. In: Böcker W, Denk H, Heitz P (eds). *Pathologie*, 3. edn, Elsevier GmbH: München, Jena, 2004, pp 831-64.
30. Sauter G, Moch H, Mihatsch M. Prädiktive molekulare Pathologie oder das Titanic-Szenario. *Schweiz Med Forum* 2004; 1/2:26-8.
31. Struckmann K, Moch H. Identification and Characterization of Genetical Alterations involved in Renal Tumor Biology. In: Nunez K (ed). *Focus on Kidney Cancer Research*, Nova Biomedical, Inc.: New York, 2005.
32. Moch H. Oncocytomas and rare renal tumors. In: Waxman J (ed). *Urological Cancers*, Springer-Verlag London: New York, 2005, pp 301-8.
33. Moch H. Chip-Diagnostik beim Mammakarzinom. *Senologie* 2006; 2:X-XI.

34. Moch H, Passweg JR. [Molecular diagnosis/molecular therapy]. *Ther Umsch* 2006; 63(4):231-2.
35. Moch H, Storz M. Tissue Microarrays and Biomarker Validation. In: Cheng L, Zhang D (eds). *Essentials of Molecular Genetic Pathology*, Humana Press/Springer Inc.: Totowa, NJ, 2007.
36. Moch H. Brustkrebs - Welche Prognoseparameter kann eine moderne Pathologie bestimmen? *Journal für Menopause/Medizin für die Frau* 2007; 2(4):14-6.
37. Ravaioli A, Monti F, Regan MM, Maffini F, Mastropasqua MG, Spataro V, Castiglione-Gertsch M, Panzini I, Gianni L, Goldhirsch A, Coates A, Price KN, Gusterson BA, Viale G. p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. *Ann Oncol* 2008; 19(4):660-8.
38. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovacs A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. *J Clin Oncol* 2008; 26(9):1404-10.
39. Fuchs T, Lange T, Wild P, Moch H, Buhmann J. Weakly Supervised Cell Nuclei Detection and Segmentation on Tissue Microarrays of Renal Clear Cell Carcinoma. *Pattern Recognition*, Vol. 5096/2008, Springer Berlin / Heidelberg, 2008, pp 173-82.
40. Fuchs T, Lange T, Wild P, Moch H, Buhmann J. Computational Pathology Analysis of Tissue Microarrays Predicts Survival of Renal Clear Cell Carcinoma Patients. *Medical Image Computing and Computer-Assisted Intervention - MICCAI 2008*, Springer: Heidelberg/Berlin, 2008.
41. Böcker W, Denk H, Heitz PU, Moch H (eds). *Pathologie*. Elsevier GmbH: München, Jena, 2008.
42. Böcker W, Denk H, Heitz PU, Moch H (eds). *Repetitorium Pathologie*. Elsevier GmbH: München, Jena, 2008.
43. Nizze H, Kerjaschki D, Moch H. Niere. In: Böcker W, Denk H, Heitz PU, Moch H (eds). *Pathologie*, 4. edn, Elsevier GmbH: München, Jena, 2008, pp 853-88.
44. Storz M, Moch H. Tissue Microarrays and Biomarker Validation. In: Cheng L, Zhang DY (eds). *Molecular Genetic Pathology*, Humana Press: New York, 2008, pp 133-40.
45. Moch H, Knuth A, Kleihues P (eds). *Targets for Cancer Prevention and Therapy*. Ponte Press: Bochum, 2009.
46. Ceschi M, Bopp M, Dick A, Probst-Hensch N, Gutzwiller F, Moch H. *Krebs im Kanton Zürich. Ein Bericht des Krebsregisters*, Vol. Nr. 15, Institut für Sozial- und Präventivmedizin: Zürich, 2009.
47. Egevad L, Algaba F, Berney DM, Boccon-Gibod L, Griffiths DF, Lopez-Beltran A, Mikuz G, Varma M, Montironi R. The European Network of Uropathology: a novel mechanism for communication between pathologists. *Anal Quant Cytol Histol* 2009; 31(2):90-5.

48. Giobbie-Hurder A, Price KN, Gelber RD. Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. *Clin Trials* 2009; 6(3):272-87.
49. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thurlimann B, Paridaens R, Smith I, Mauriac L, Forbes JF, Price KN, Regan MM, Gelber RD, Coates AS. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. *N Engl J Med* 2009; 361(8):766-76.
50. Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thurlimann B, Mouridsen H, Campone M, Forbes JF, Paridaens RJ, Colleoni M, Pienkowski T, Nogaret JM, Lang I, Smith I, Gelber RD, Goldhirsch A, Coates AS. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. *Ann Oncol* 2009; 20(9):1489-98.
51. Moch H (ed). *Verhandlungen der Deutschen Gesellschaft für Pathologie*. Springer Medizin Verlag GmbH: Freiburg, 2009, 106-260 pp.
52. Weber A, Zimmermann D, Moch H. KRAS-Diagnostik. In: Köberle D, Gautschi O (eds). *KRAS-Mutationsstatus und kolorektales Karzinom*, 1. edn, UNI-MED Verlag AG: Bremen, 2010.
53. Moch H (ed). *Verhandlungen der Deutschen Gesellschaft für Pathologie*. Springer Medizin Verlag GmbH: Berlin, 2010, 116-339 pp.
54. Kirkali Z, Mulders P, (eds). *Pathology of Renal Cancer. Proceedings of the 1st EAU-ICD International Consultation on Kidney Cancer* 2010: Editions 21.
55. Moch H (ed). *Verhandlungen der Deutschen Gesellschaft für Pathologie*. Springer Medizin Verlag GmbH: Berlin, 2011, 156-402 pp.
56. Böcker W, Denk H, Heitz PU, Höfler G, Kreipe H, Moch H. *Pathologie*, 5. edn, Elsevier: München, 2012.
57. Moch H (ed). *Verhandlungen der Deutschen Gesellschaft für Pathologie*. Springer: Berlin, 2012, 183-404 pp.
58. Moch H, Kerjaschki D, Kain R, Amann K. Niere. In: Böcker W, Denk H, Heitz PU, Höfler G, Kreipe H, Moch H (eds). *Pathologie*, 5. edn, Elsevier: München, 2012, pp 693-720.
59. Moch H. Klassifikation und molekulare Veränderungen des Nierenzellkarzinoms-Diagnostische und therapeutische Aspekte. *Schweizer Zeitschrift für Onkologie* 2013; 3:5-9.
60. Moch H (ed). *Verhandlungen der Deutschen Gesellschaft für Pathologie*. Springer: Berlin, 2013, 167-348 pp.
61. A genomics-based classification of human lung tumors. *Sci Transl Med* 2013; 5(209):209ra153.
62. Moch H, Rössle M. Von der personalisierten Diagnostik zur individualisierten Medizin. In: Marti R (ed). *Krebsforschung in der Schweiz*, Krebsliga Schweiz: Bern, 2013, pp 61-4.

63. Storz M, Moch H. Tissue Microarrays and Biomarker Validation in Molecular Diagnostics. In: Cheng L, Zhang DY, Eble JN (eds). *Molecular Genetic Pathology*, 2nd edn, Vol. 2, Springer: New York, Heidelberg, Dordrecht, London, 2013, pp 455-64.
64. Tag B, Moch H. Symposium Autopsie und Religion. Deutsche Akademie der Wissenschaften Leopoldina: Halle 2013. Report No.
65. Moch H (ed). *98. Jahrestagung der Deutschen Gesellschaft für Pathologie*. Springer: Berlin, 2014, 167-340 pp.
66. Moch H. Kidney Cancer. In: Stewart BW, Wild CP (eds). *World Cancer Report*, International Agency for Research on Cancer (IARC): Lyon, 2014, pp 2-9.
67. Moch H (ed). *99. Jahrestagung der Deutschen Gesellschaft für Pathologie*. Springer: Berlin, 2015.
68. Störkel S, Wild PJ, Moch H. Nierentumoren im Erwachsenenalter. In: Amann K, Kain R, Klöppel G (eds). *Urogenitale und Endokrine Organe, Gelenke und Skelett*, 3rd edn, Springer: Berlin, Heidelberg, 2015, pp 444-85.
69. Moch H, Amin MB, Argani P, Cheville J, Delahunt B, Martignoni G, Medeiros LJ, Srigley JR, Tan PH, Tickoo SK. Renal cell tumours. In: Moch H, Humphrey PA, Ulbright TM, Reuter VE (eds). *WHO Classification of Tumours of the Urinary System and Male Genital Organs*, 4th edn, IARC: Lyon, 2016, pp 14-7.
70. Moch H, Humphrey PA, Ulbright TM, Reuter VE. *WHO Classification of Tumours of the Urinary System and Male Genital Organs*, 4th edn, IARC: Lyon, 2016.
71. Amin MB, Moch H, Alkan S, Marques Maggio E. Renal haematopoietic neoplasms. In: Moch H, Humphrey PA, Ulbright TM, Reuter VE (eds). *WHO Classification of Tumours of the Urinary System and Male Genital Organs*, 4th edn, IARC: Lyon, 2016, pp 73-5.
72. Cubilla AL, Amin MB, Ayala A, Ayala G, Chaux A, Corbishley C, Dillner J, Moch H, Sanchez DF, Soares FA, Tamboli P, Young RH. Malignant epithelial tumours of the penis. In: Moch H, Humphrey PA, Ulbright TM, Reuter VE (eds). *WHO Classification of Tumours of the Urinary System and Male Genital Organs*, 4th edn, IARC: Lyon, 2016, pp 262-76.
73. Delahunt B, Algabe F, Cheville J, Amin MB, Argani P, Martignoni G, Moch H, Srigley JR, Tan PH, Tickoo SK. Papillary renal cell carcinoma. In: Moch H, Humphrey PA, Ulbright TM, Reuter VE (eds). *WHO Classification of Tumours of the Urinary System and Male Genital Organs*, 4th edn, IARC: Lyon, 2016, pp 23-5.
74. Delahunt B, Cheville J, Moch H. Haemangioblastoma. In: Moch H, Humphrey PA, Ulbright TM, Reuter VE (eds). *WHO Classification of Tumours of the Urinary System and Male Genital Organs*, 4th edn, IARC: Lyon, 2016, p 67.
75. Eble JN, Moch H, Amin MB, Argani P, Cheville J, Delahunt B, Martignoni G, Srigley JR, Tan PH, Tickoo SK. Papillary adenoma. In: Moch H, Humphrey PA, Ulbright TM, Reuter VE (eds). *WHO Classification of Tumours of the Urinary System and Male Genital Organs*, 4th edn, IARC: Lyon, 2016, pp 42-3.
76. Hes O, Moch H, Reuter VE. Oncocytoma. In: Moch H, Humphrey PA, Ulbright TM, Reuter VE (eds). *WHO Classification of Tumours of the Urinary System and Male Genital Organs*, 4th edn, IARC: Lyon, 2016, pp 43-4.

77. Moch H, Amin MB, Srigley JR. Germ cell tumours. In: Moch H, Humphrey PA, Ulbright TM, Reuter VE (eds). WHO Classification of Tumours of the Urinary System and Male Genital Organs, 4th edn, IARC: Lyon, 2016, p 75.
78. Moch H, Bonsib SM, Dealhunt B, Eble JN, Egevad L, Grignon DJ, Linehan WM, Reuter VE, Srigley JR, Sulser T, Tan PH. Clear cell renal cell carcinoma. In: Moch H, Humphrey PA, Ulbright TM, Reuter VE (eds). WHO Classification of Tumours of the Urinary System and Male Genital Organs, IARC: Lyon, 2016, pp 18-21.
79. Moch H, Cheville J. Neuroendocrine tumours. In: Moch H, Humphrey PA, Ulbright TM, Reuter VE (eds). WHO Classification of Tumours of the Urinary System and Male Genital Organs, 4th edn, IARC: Lyon, 2016, pp 72-3.
80. Montironi R, Cheng L, Lopez-Beltran A, Michal M, Moch H. Multilocular cystic renal neoplasm of low malignant potential. In: Moch H, Humphrey PA, Ulbright TM, Reuter VE (eds). WHO Classification of Tumours of the Urinary System and Male Genital Organs, 4th edn, IARC: Lyon, 2016, p 22.
81. Paner G, Amin MB, Moch H, Störkel S. Chromophobe renal cell carcinoma. In: Moch H, Humphrey PA, Ulbright TM, Reuter VE (eds). WHO Classification of Tumours of the Urinary System and Male Genital Organs, 4th edn, IARC: Lyon, 2016, pp 27-8.
82. Velázquez EF, Amin MB, Cubilla AL, Jenkins D, Moch H, Piris A, Quint WGV. Precursor lesions of the penis. In: Moch H, Humphrey PA, Ulbright TM, Reuter VE (eds). WHO Classification of Tumours of the Urinary System and Male Genital Organs, 4th edn, IARC: Lyon, 2016, pp 277-9.
83. Moch H (ed). *100. Jahrestagung der Deutschen Gesellschaft für Pathologie e.V.* Springer: Berlin, 2016, S158-S278 pp.
84. Moch H (ed). *101. Jahrestagung der Deutschen Gesellschaft für Pathologie e.V.* Springer: Berlin, 2017, S150-S263 pp.